Archive for April, 2016

(GSAT) to Participate in 20th Annual Burkenroad Reports Investment Conference

COVINGTON, La., April 22, 2016 — Globalstar Inc. (NYSE MKT:GSAT) announced today that it will participate in the 20th Annual Burkenroad Reports Investment Conference in New Orleans, LA. Jay Monroe, Chairman and CEO, will present at 11:00 a.m. CDT at the New Orleans Ritz-Carlton Hotel on Friday, April 22, 2016.

A copy of the presentation will be made available on the Investor Relations page of Globalstar’s website.

About Globalstar, Inc.
Globalstar is a leading provider of mobile satellite voice and data services, leveraging the world’s newest mobile satellite communications network. Customers around the world in industries like government, emergency management, marine, logging, oil & gas and outdoor recreation rely on Globalstar to conduct business smarter and faster, maintain peace of mind and access emergency personnel.  Globalstar data solutions are ideal for various asset and personal tracking, data monitoring and SCADA applications.  The Company’s products include mobile and fixed satellite telephones, the innovative Sat-Fi satellite hotspot, Simplex and Duplex satellite data modems, tracking devices and flexible service packages.  For more information, visit www.globalstar.com.

Note that all SPOT products described in this press release are the products of SPOT LLC, which is not affiliated in any manner with Spot Image of Toulouse, France or Spot Image Corporation of Chantilly, Virginia. For more information, visit www.globalstar.com.

Investor Contact Information:
Email: investorrelations@globalstar.com 
Phone: (985) 335-1538
Friday, April 22nd, 2016 Uncategorized Comments Off on (GSAT) to Participate in 20th Annual Burkenroad Reports Investment Conference

(ARTX) ISS Recommends Shareholders Vote “FOR” Management Proposals

ANN ARBOR, Mich., April 21, 2016  — Arotech Corporation (Nasdaq GM: ARTX) today announced that Institutional Shareholder Services (“ISS”) has joined another leading independent proxy advisory firm in recommending that shareholders vote “FOR” on all three proposals being presented by Arotech’s Board of Directors at the Annual Meeting of Shareholders to be held on May 4, 2016. Specifically, ISS has recommended a vote for the election of the proposed Class III director nominees, ratification of the appointment of the Company’s independent auditors and the compensation of the Company’s executive officers.

“After a thorough and independent review, ISS has recommended voting in favor of all of the matters to be presented at our annual shareholders meeting,” said Steven Esses, President and CEO of Arotech. “Each of the three proposals supports our commitment to transparency, independence and strong corporate governance. This is the second independent institutional investor research organization to have recommended in favor of all of the board’s proposals.”

The Company filed its definitive proxy statement relating to the Annual Meeting (the “Proxy Statement”) with the Securities and Exchange Commission (the “SEC”) on March 30, 2016.  Shareholders can obtain the Proxy Statement, any amendments or supplements to the Proxy Statement and other documents filed by the Company with the SEC for no charge at the SEC’s website at www.sec.gov and at the Company’s website at www.arotech.com.

Shareholders are urged to vote “FOR” the three proposals. Shareholders may vote by telephone, Internet or by returning a signed proxy or voting instruction form by mail. Investors with questions regarding how to vote their shares may contact the firm’s proxy solicitor, Alliance Advisors LLC, at 973.873.7700.

About Arotech Corporation

Arotech Corporation is a leading provider of quality defense and security products for the military, law enforcement and homeland security markets, including multimedia interactive simulators/trainers and advanced zinc-air and lithium batteries and chargers. Arotech operates two major business divisions: Training and Simulation, and Power Systems.

Arotech is incorporated in Delaware, with corporate offices in Ann Arbor, Michigan, and research, development and production subsidiaries in Michigan, South Carolina, and Israel. For more information on Arotech, please visit Arotech’s website at www.arotech.com.

Arotech Investor Relations Contacts:

Brett Maas / Rob Fink
Hayden IR
(646) 536.7331 / (646) 415.8972
ARTX@haydenir.com

Except for the historical information herein, the matters discussed in this news release include forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, readers are cautioned not to place undue reliance on these forward-looking statements, as they are subject to various risks and uncertainties that may cause actual results to vary materially. These risks and uncertainties include, but are not limited to, risks relating to: product and technology development; the uncertainty of the market for Arotech’s products; changing economic conditions; delay, cancellation or non-renewal, in whole or in part, of contracts or of purchase orders (including as a result of budgetary cuts resulting from automatic sequestration under the Budget Control Act of 2011); and other risk factors detailed in Arotech’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and other filings with the Securities and Exchange Commission. Arotech assumes no obligation to update the information in this release. Reference to the Company’s website above does not constitute incorporation of any of the information thereon into this press release.

Thursday, April 21st, 2016 Uncategorized Comments Off on (ARTX) ISS Recommends Shareholders Vote “FOR” Management Proposals

(VIAB) & (HAS) Tap Top Group Of Writers To Create Cross-Property Film Universe

HOLLYWOOD, Calif., April 21, 2015  — Paramount Pictures and Hasbro, Inc. today unveiled its top talent writers room which will have responsibility for developing Hasbro’s cross-property interconnected onscreen universe featuring the brands G.I. Joe, Micronauts, Visionaries, M.A.S.K. (Mobile Armored Strike Kommand) and ROM. This group includes some of the most notable creative talent in Hollywood, including Academy Award Winner Akiva Goldsman (A Beautiful Mind), who will have responsibility for overseeing the writers room on behalf of Hasbro and Paramount as well as serving as Executive Producer for all of the films. Joining Goldsman will be Lindsey Beer (Wizard of Oz, Kingkiller Chronicle), Pulitzer Prize Winner Michael Chabon (The Amazing Adventures of Kavalier & Clay), Cheo Coker (Luke Cage, Ray Donovan), Joe Robert Cole (Black Panther, People vs. OJ), Nicole Perlman (Guardians of the Galaxy, Captain Marvel), Jeff Pinkner (Lost, The Dark Tower), Nicole Riegel (LYNCH), Geneva Robertson (Atlantis, Tomb Raider) and Brian K Vaughan (Under the Dome, Lost).

Allspark Pictures, Hasbro’s film label, plans to produce films based on this cross-property universe, with Brian Goldner (Chairman, President and CEO, Hasbro) and Stephen Davis (Executive Vice President and Chief Content Officer, Hasbro) serving as Producers, and Josh Feldman (Co-Head of Storytelling, Hasbro) as Co-Executive Producer. Hasbro will also deploy in the room an unprecedented team of its top artists and designers to assist Goldsman and the writers to visualize this all-new cinematic universe.

“Paramount and Hasbro have partnered on many successful films in the past, including the ‘TRANSFORMERS’ and ‘G.I. JOE,’ franchises,” said Brad Grey, Chairman and CEO of Paramount Pictures. “Bringing together a writers room of this caliber is a bold step for our partnership, and one that we believe is critical for building these brands into new, successful franchises for the future.”

“Together with Paramount, we have assembled a team of incredibly talented creative minds and storytellers to continue to help tell the rich history and narrative behind this interconnected cinematic universe, and we are thrilled to be working with Akiva Goldsman again to guide this process,” said Brian Goldner. “We are also excited to partner with Paramount to produce the films, as we’ve had a strong and collaborative partnership since our first Transformers movie in 2007.”

The Paramount and Hasbro partnership is responsible for the worldwide blockbuster success of the “TRANSFORMERS” franchise, which has earned $3.8 billion to-date, and whose films, directed by Michael Bay, are amongst the highest grossing movies of all time; and the “G.I. JOE” franchise, which have earned more than $675 million worldwide.

About Paramount Pictures Corporation

Paramount Pictures Corporation (PPC), a global producer and distributor of filmed entertainment, is a unit of Viacom (NASDAQ: VIAB, VIA), a leading content company with prominent and respected film, television and digital entertainment brands. Paramount controls a collection of some of the most powerful brands in filmed entertainment, including Paramount Pictures, Paramount Animation, Paramount Television, Paramount Vantage, Paramount Classics, Insurge Pictures, MTV Films, and Nickelodeon Movies. PPC operations also include Paramount Home Media Distribution, Paramount Pictures International, Paramount Licensing Inc., and Paramount Studio Group.

ABOUT HASBRO

Hasbro (NASDAQ: HAS) is a global company committed to Creating the World’s Best Play Experiences, by leveraging its beloved brands, including LITTLEST PET SHOP, MAGIC: THE GATHERING, MONOPOLY, MY LITTLE PONY, NERF, PLAY-DOH and TRANSFORMERS, and premier partner brands. From toys and games, television programming, motion pictures, digital gaming and lifestyle licensing, Hasbro fulfills the fundamental need for play and connection with children and families around the world. The Company’s Hasbro Studios and its film label, ALLSPARK PICTURES, create entertainment brand-driven storytelling across mediums, including television, film, digital and more. Through the company’s commitment to corporate social responsibility, including philanthropy, Hasbro is helping to build a safe and sustainable world and to positively impact the lives of millions of children and families. Learn more at www.hasbro.com, and follow us on Twitter (@Hasbro & @HasbroNews) and Instagram (@Hasbro).

Media Contact:
Katie Martin Kelley
(323) 956-2821
kmk@paramount.com

Julie Duffy
(401) 727-5931
Julie.Duffy@hasbro.com

Melissa Schumer/Mat Newman
(310) 854-8154/(310) 854-8198
mschumer@rogersandcowan.com
mnewman@rogersandcowan.com

Thursday, April 21st, 2016 Uncategorized Comments Off on (VIAB) & (HAS) Tap Top Group Of Writers To Create Cross-Property Film Universe

(AMD) PC Gaming Showcase to Return to LA During E3 in Second Annual PC Gaming Show

Powered by PC Gamer with Presenting Partner AMD, PC Gaming Show Event to be Livestreamed from LA on June 13

AMD, Bohemia Interactive and Tripwire Interactive Return as Sponsors

LOS ANGELES, April 21, 2016  — “AMD Presents The PC Gaming Show Powered by PC Gamer,” the second annual event for developers, publishers, hardware companies, press and fans, will take place at The Theatre at Ace Hotel in Los Angeles on Monday, June 13 at 12 noon PDT. Presented by AMD, organized by PC Gamer, and streamed live in partnership with Twitch, the show will once again unite and energize the PC gaming community with exclusive news, fresh reveals and perspective from some of the most respected names in the industry. Sponsors and participants from last year’s inaugural PC Gaming Show included game developers and industry titans like, ArenaNet, Blizzard, Cloud Imperium, Creative Assembly, Microsoft and Nexon.

For more information and to register for press access, please visit: www.PCGamingShow.com and follow #pcgamingshow.

With the success of last year’s inaugural show, which boasted 30 on-stage guests and over one million live viewers, the 2016 PC Gaming Show promises an exciting lineup of announcements and participants. PC gaming continues to be the most powerful and affordable platform for gamers – and with innovation in virtual reality and esports, it’s soon to reach more people than ever before. The PC Gaming Show celebrates the PC community that’s always been, and the PC community that’s on the horizon.

“AMD is once again proud to shine the spotlight on the games, tech and people behind PC gaming that make such a thriving and impassioned community possible,” said Gerald Youngblood, Director of Worldwide Channel Marketing & Communications. “AMD’s focus is creating the best experience for PC gamers and the PC Gaming Show at E3 is the perfect avenue for the fans and gamers to get the news that matters to them, first.”

Organized by PC Gamer, with support from Presenting Partner, AMD (NASDAQ: AMD), the second annual PC Gaming Show will see participation from a range of game developers, including Bohemia Interactive, SEGA and Tripwire Interactive, among many others to be announced soon.

“We created the PC Gaming Show last year because E3 lacked an event designed to celebrate the amazing experiences possible on the platform we love,” said Tim Clark, Global Editor-in-Chief, PC Gamer. “We’re thrilled to be coming back this year, with a refined format and even more cool stuff to showcase.”

About PC Gamer
PC Gamer is the global authority on PC games. For more than 20 years, it has delivered unrivaled coverage, in print and online, of every aspect of PC gaming. Our team of experts brings readers trusted reviews, component testing, strange new mods, under-the-radar indie projects and breaking news around-the-clock from all over the world.

Thursday, April 21st, 2016 Uncategorized Comments Off on (AMD) PC Gaming Showcase to Return to LA During E3 in Second Annual PC Gaming Show

(CXRX) Announces Formation of Special Committee to Review Strategic Alternatives

OAKVILLE, ON, April 21, 2016  – Concordia Healthcare Corp. (“Concordia” or the “Company”) (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced it has formed a special committee of independent members of the Board of Directors of the Company (the “Special Committee”) to consider various strategic alternatives potentially available to the Company.

The Company has had discussions, however, there can be no assurance that any transaction will occur.  Concordia does not intend to make any additional comments at this time regarding various strategic alternatives potentially available to the Company.

About Concordia

Concordia is a diverse, international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs. The Company has an international footprint with sales in more than 100 countries, and has a diversified portfolio of more than 200 established off-patent molecules. Concordia also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin® for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications.

Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.

Notice regarding forward-looking statements and information:

This news release includes forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws, regarding Concordia and its business, which may include, but are not limited to any strategic alternatives potentially available to the Company. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks relating to Concordia’s securities, Concordia’s growth, risks associated with the use of Concordia’s products, increased leverage, the inability to generate cash flows, revenues and/or stable margins, the inability to grow organically or through M&A, the inability to repay debt and/or satisfy future obligations (including, without limitation, earn out obligations), risks associated with Concordia’s outstanding debt, risks associated with the geographic markets in which Concordia operates, the pharmaceutical industry and the regulation thereof, economic factors, the equity and debt markets generally, general economic and stock market conditions, risks associated with fluctuations in exchange rates (including, without limitation, fluctuations in currencies), risks and uncertainties detailed from time to time in Concordia’s filings with the Securities and Exchange Commission and the Canadian Securities Administrators, and many other factors beyond the control of Concordia. Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events, or otherwise.

Thursday, April 21st, 2016 Uncategorized Comments Off on (CXRX) Announces Formation of Special Committee to Review Strategic Alternatives

(CNCK) Dr. Goran Skog Joins Content Checked’s Board of Directors

LOS ANGELES, CA–(Apr 21, 2016) – Content Checked Holdings, Inc. (OTCQB: CNCK) (the “Company”), a creator of mobile applications for people with dietary restrictions, today announced that Dr. Göran Rune Skog, an accomplished physician with more than 35 years of experience in the field of medicine, has been elected to the Company’s board of directors.

“Dr. Göran Skog brings considerable medical and nutritional experience, as well as specialty in orthopedic medicine, physical medicine, research and surgery, invasive pain management and rehabilitation. He has worked in a number of leading Scandinavian medical centers, was the team physician for the Swedish Olympic and national sports teams and has been responsible for pre-season training and dietary optimization for world-class athletes. Göran understands the critical role that nutrition plays in everyday life and knows nutrition strategies that really make sense,” said Kris Finstad, the Company’s CEO and President. Mr. Finstad further states, “We look forward to benefiting from Göran’s medical and nutritional experience as well as his knowledge and medical community network.”

“We were determined to find a board member with all of the attributes that Göran embodies and we are proud to welcome such an outstanding individual and leading medical authority to our board,” continued Mr. Finstad. “I am confident that Göran is going to make a significant and positive impact on our Company.”

“I have a long-term interest in nutritional, dietary, medical technology and the process of guiding innovative companies to make a positive impact in people’s lives, hit business milestones and expand into new markets,” said Dr. Göran Skog. “I am excited by what Content Checked has accomplished and I am honored to be joining their board.”

Dr. Skog is a distinguished physician, specializing in orthopedic medicine, physical medicine, research and surgery, invasive pain management and rehabilitation. He currently serves as the Head of the Spine Treatment Unit at the NIMI Hospital in Oslo, Norway. He maintains a private practice in central Stockholm, Sweden and serves as the Associate Professor at Cedarcrest Hospitals in Abuja, Nigeria. Dr. Skog previously served as the CEO and Director of the Swedish Orthopedic Medicine Society and has performed research focusing on percutaneous disc surgery, knee and hip cartilage arthrosis and rehabilitation, and disc nutrition via micro-dialysis as related to low back pain. He formerly served as the physician for the Swedish National Alpine Ski and Winter Olympic teams and as the medical director for the Swedish Ski Areas Organization, the Alpine Search & Rescue of Sweden and Sea Search & Rescue of Sweden. Dr. Skog currently serves on the board of directors of Active Life Foundation, SEB (Skandinaviska Enskilda Banken). Dr. Skog received a Bachelor of Science in Psychology from the University of Stockholm, a Bachelor of Science in Zoology from the University of Tulsa and a Doctor of Medicine from the Oklahoma State University.

About Content Checked Holdings, Inc.

Content Checked Holdings, Inc. (www.contentchecked.com) has created a revolutionary marketplace for people with dietary restrictions and the organizations who cater to them by creating and introducing the ContentChecked, MigraineChecked and SugarChecked smartphone applications. ContentChecked and MigraineChecked are the first applications with comprehensive and accurate content information, and in-depth allergen and migraine definitions for over 70% of conventional U.S. food products.

Each app gives consumers the ability to scan a product’s bar code and determine if it is safe for consumption based on their allergy settings. The apps will recommend a suitable alternative if a product does contain one or more of a user’s allergens. This enables the applications to meet the needs of millions of people in the U.S. In the U.S. alone, there are more than 15 million people who suffer from food allergies and 38 million people who suffer from migraines and chronic headaches. The food allergy and intolerances market has been valued at approximately US$13 billion in 2015. As a result, the Company has created a pivotal way for food manufacturers and producers to showcase their products to consumers who are actively seeking them at the point of purchase.

The Company has created a robust database of allergens, migraine triggers and food ingredients that directly correlate with food allergies, intolerances, migraines and chronic headaches. There are currently hundreds of thousands of products in its database, updated regularly. All applications serve as easy shopping tools for consumers to decipher often misleading food labels and receive recommendations for healthier alternative products as they shop in real time. The Company’s mission is to offer fast, reliable and efficient mobile apps that help consumers make more informed purchasing decisions and live healthier lives in accordance to their dietary preferences.

For more information on the Company, please visit its social media channels via Facebook (www.facebook.com/contentchecked), (www.facebook.com/migrainechecked) and (www.facebook.com/sugarchecked); Instagram (www.instagram.com/contentchecked), (www.instagram.com/migrainechecked) and (www.instagram.com/sugarchecked); or
YouTube (www.youtube.com/channel/UCMihoaZILlRZ2C3hmx5vXhQ).

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2015, the Company’s Quarterly Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Contacts:

Investor Relations

Christine J. Petraglia
Managing Director, Investor Relations
PCG Advisory Group
535 5th Avenue, 24th Floor
New York, NY 10017
646-731-9817
www.pcgadvisory.com

Content Checked Holdings, Inc.

Victoria Nunez
Director of Business Development
8730 Sunset Blvd., Suite 240
West Hollywood, CA 90069
424-205-1777
www.contentchecked.com

Thursday, April 21st, 2016 Uncategorized Comments Off on (CNCK) Dr. Goran Skog Joins Content Checked’s Board of Directors

(REI) Announces Common Stock Offering

Ring Energy, Inc. (NYSE MKT: REI) (the “Company”) announced today that it intends to offer shares of its common stock in an underwritten public offering. The underwriters will have a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The Company intends to use the net proceeds from the offering to fund a pilot horizontal drilling program, repay debt under its revolving credit facility and for general corporate purposes.

SunTrust Robinson Humphrey, Inc. and Seaport Global Securities LLC are acting as joint book-running managers in the offering.

The offering will be made only by means of a prospectus supplement and accompanying base prospectus to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A copy of the preliminary prospectus supplement and accompanying base prospectus for the offering will be filed with the SEC and may be obtained from the SEC’s website at http://www.sec.gov. In addition, copies may be obtained, when available, by contacting (i) SunTrust Robinson Humphrey, 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention: Prospectus Department; email: strh.prospectus@suntrust.com; telephone: 404-926-5744; or fax: 404-926-5464 or (ii) Seaport Global Securities LLC, 360 Madison Avenue, 21st Floor, New York, NY 10017; or telephone: 646-264-5601.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Ring Energy, Inc.

Ring Energy, Inc. is an oil and gas exploration, development and production company with current operations in Texas and Kansas.

www.ringenergy.com

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995 that involve a wide variety of risks and uncertainties, including, without limitations, statements with respect to the Company’s strategy and prospects. Such statements are subject to certain risks and uncertainties which are disclosed in the Company’s reports filed with the SEC, including its Form 10-K for the fiscal year ended December 31, 2015, and its other filings with the SEC. Readers and investors are cautioned that the Company’s actual results may differ materially from those described in the forward-looking statements due to a number of factors, including, but not limited to, the Company’s ability to acquire productive oil and/or gas properties or to successfully drill and complete oil and/or gas wells on such properties, general economic conditions both domestically and abroad, the conduct of business by the Company, and other factors that may be more fully described in additional documents set forth by the Company.

 

K M Financial, Inc.
Bill Parsons, 702-489-4447

Wednesday, April 20th, 2016 Uncategorized Comments Off on (REI) Announces Common Stock Offering

(SHLD) Kenmore®, Craftsman® And DieHard® Debut Connected Home Products

Trusted Brands Deliver Solutions to Make Members’ Lives Easier and Provide Peace-Of-Mind, While Saving Time and Money

HOFFMAN ESTATES, Ill., April 20, 2016  — For generations, the Kenmore, Craftsman and DieHard brands have provided homeowners with the appliances, tools and power needed to make their house a home. Today, the brands announced they will introduce five affordable connected products designed to protect the home and garage, provide peace-of-mind, and save time, energy and money.

“The Kenmore, Craftsman and DieHard brands are part of the fabric of American homes,” said Tom Park, president of Kenmore, Craftsman and DieHard brands at Sears Holdings. “Our members rely on our products’ quality and performance not only in their daily lives, but for years to come. We’re excited to unveil these new, connected products designed to meet the needs of the modern homeowner, making home management easier and more cost-effective.”

The initial product offering includes:
Kenmore, an industry leader in delivering trusted performance:

Craftsman, America’s most trusted tool brand:

  • Wireless-enabled Craftsman Zero Turn Steerable Riding Mower

DieHard, America’s most trusted, reliable and preferred vehicle battery brand:

  • DieHard Smart Charger and Maintainer

Easy-to-use apps will also be introduced to provide homeowners with remote access from their smartphone or tablet to monitor efficiencies and adjust product settings, which can lead to energy cost savings.

The Kenmore Elite Smart Room Air Conditioner is available now, with the additional products to follow. The connected products will be available in select Sears stores nationwide and online at Sears.com as part of its Connected Solutions offering, which provides ways for members to streamline their routine, save money and put control of their home in the palm of their hand.

Kenmore Elite 8,000 BTU Smart Room Air Conditioner

  • The Kenmore Elite Smart Room Air Conditioner offers a stylish new design that allows members to cool their homes from almost anywhere using the Kenmore AC™ app. With wireless accessibility from a smartphone or tablet, members can:
    • Control on the go: Remotely turn product on and off, set a schedule or adjust temperature while away.
    • Conserve energy: Smart technology provides the ability to run only when needed, saving energy and money.
    • Model: 77082
    • MSRP: $299.99

Kenmore Smart Water Heater Module

  • The Kenmore Smart Water Heater Module allows members to connect to select new and existing Kenmore and Kenmore Elite Water Heaters to monitor and adjust home water temperature and usage. The Kenmore Smart Control app will assist users with:
    • Energy savings: Save energy and money on hot water generation by adjusting the temperature setting on the water heater when away from home.
    • Water monitoring: View available hot water levels to monitor how much hot water is left.
    • Model: 58000
    • MSRP: $69.99                                                                   

Kenmore Elite Smart Hybrid Water Softener

  • The Kenmore Elite Smart Hybrid Water Softener allows homeowners to monitor salt levels and water usage remotely to prevent wasted resources. This water softener connects to the Kenmore Smart Control app to help users:
    • Manage salt levels: Monitor the inner salt supply and eliminate the surprise of an unexpected need for replenishment.
    • Water flow rate monitoring: Keep informed on water flow rate, current day water usage and average daily water usage to easily identify excessive usage and unexpected continuous water flow.
    • Model: 38620
    • MSRP: $799.99

Wireless-enabled Craftsman Zero Turn Steerable Riding Mowers

  • The Craftsman Zero Turn Steerable Riding Mowers are designed for ease of use, especially when mowing large yards with obstacles. These wireless-enabled riding mowers connect with a smartphone or tablet via the new Craftsman Connect app to help riders in the following ways:
    • Maintenance checks: Notification alerts members when it’s time to change the oil, replace the air filter, check blades and wheel alignment, schedule maintenance, and more.
    • Product care: View do-it-yourself maintenance videos and step-by-step tutorials on changing blades, replacing the air filter and changing oil.
    • Product information: Owner’s manual, parts, attachments and accessories list.
    • Model:
      • 22 HP V-Twin 42-in. Zero Turn Steerable Riding Mower: 20400
      • 23 HP V-Twin 50-in. Zero Turn Steerable Riding Mower: 20410
    • MSRP
      • 22 HP V-Twin 42-in. Zero Turn Steerable Riding Mower: $2,799
      • 23 HP V-Twin 50-in. Zero Turn Steerable Riding Mower: $3,199

DieHard Smart Charger and Maintainer

  • The DieHard Smart Charger and Maintainer allows members to monitor their motorcycle, car or boat’s battery health remotely, all with their smart phone or tablet. Equipped with auto voltage detection, members can now use one DieHard Smart Charger and Maintainer for 6-volt and 12-volt batteries.
    • Stay charged: Automatically keeps batteries fully charged and maintained at all times.
    • Digital Scrolling Display: An alphanumeric display guides members through the charging process eliminating the guesswork.
    • Model: DH111
    • MSRP: $99.99

Additional Kenmore, Craftsman and DieHard connected products will arrive in stores throughout the remainder of 2016.

For more information about current and future smart products visit Kenmore.com/Smart. The complete line of Kenmore appliances can also be found online at Kenmore.com; Craftsman tools at Craftsman.com; and DieHard products at DieHard.com.

About the Kenmore Brand

The Kenmore Brand is an industry leader in delivering trusted performance in the home with smart and stylish appliance innovations that help consumers do things quicker, easier and better. Recognized as a top appliance brand for over 100 years, the Kenmore brand continues to give consumers more time, efficiency and improved results for better living with industry-leading products across small and large appliance categories. For more information, visit www.kenmore.com, www.cookmore.com/press-kit/ or www.facebook.com/kenmore.

About the Craftsman Brand

The Craftsman brand is America’s most trusted tool brand. For more than 88 years, the Craftsman brand has developed innovative tools and products, earning a reputation for unsurpassed quality and durability, trusted for generations. The Craftsman brand offers a full range of hand and power tools that meet the needs of the DIY user to the demanding professional. In addition, the Craftsman brand also offers lawn and garden products and tool storage. The Craftsman brand also has a free membership program called Craftsman Club® which gives tool enthusiasts access to exclusive deals, members-only projects, expert tips and news on the latest tool innovations from the brand. Craftsman Club is part of the Shop Your Way® network, so points can be redeemed for purchases at Sears and Kmart and online at Craftsman.com. For more information, visit www.CraftsmanClub.com.

About the DieHard brand

DieHard is America’s most trusted, reliable and preferred vehicle battery brand. Introduced in 1967, Sears designed the DieHard automotive battery to produce 35 percent more usable starting power than other similar batteries. Featuring a revolutionary tough, thin-walled case of translucent polypropylene plastic, which was 50 percent thinner than conventional black rubber-type battery enclosures, the design’s extra room meant bigger plates, more acid and extra starting power. During testing, not a single failure was reported in over 26,000 starts in temperatures ranging from sub-zero to more than 100 degrees, hence the name “DieHard.” See more about DieHard at www.DieHard.com.

About Sears Holdings Corporation

Sears Holdings Corporation (NASDAQ: SHLD) is a leading integrated retailer focused on seamlessly connecting the digital and physical shopping experiences to serve our members – wherever, whenever and however they want to shop. Sears Holdings is home to Shop Your Way®, a social shopping platform offering members rewards for shopping at Sears and Kmart as well as with other retail partners across categories important to them. The Company operates through its subsidiaries, including Sears, Roebuck and Co. and Kmart Corporation, with full-line and specialty retail stores across the United States. For more information, visit www.searsholdings.com.

Larry Costello
PR Director
847-286-9036
Larry.Costello@searshc.com

Andrew Scutt
Zeno Group for Kenmore
312-245-0688
Andrew.Scutt@zenogroup.com

Wednesday, April 20th, 2016 Uncategorized Comments Off on (SHLD) Kenmore®, Craftsman® And DieHard® Debut Connected Home Products

(ARTX) Wins Marine Corps Contract, $40 Million IDIQ Award

UEC Electronics Mobile Electric Hybrid Power Sources (MEHPS) Systems to provide Marine Corp with more efficient portable solution

ANN ARBOR, Mich., April 20, 2016  — Arotech Corporation (Nasdaq GM: ARTX) today announced that its U.S. Power Systems Division, UEC Electronics, has recently received a $2.6 million contract from the Marine Corps to design, develop and deliver four MEHPS systems.

MEHPS portable solutions combine battery technology with existing generator and solar solutions to power forward deployed units. The MEHPS product harnesses solar power and intelligently reduces run-time on generators, reducing fuel consumption and extending generator life.

“The Department of Defense continues to advance initiatives that will increase energy efficiency and enable our forces to perform missions, while acknowledging energy as a potential vulnerability,” said Steven Esses, President and CEO of Arotech. “Demand for renewable and hybrid energy power generation systems continues to grow and Arotech is well positioned to capitalize on a significant opportunity. This contract award is a testament to our team and the performance of our product. We are excited about this opportunity and are optimistic that this award could lead to additional orders in the future.”

UEC Electronics previously designed and developed a smaller hybrid power solution for the Marine Corps. The 1kW Ground Renewable Expeditionary Energy Network System (GREENS) is now being produced by UEC under a $40.8 million IDIQ contract.

This latest MEHPS award is for a scalable (up to 15kW) design for use at forward operating bases and is a significant part of the DoD’s strategy to reduce fuel consumption by 25% prior to 2025. The Marine Corp’s roadmap calls for MEHPS production beginning in 2018.

International customers are watching the MEHPS program as well.  MEHPS was one of four “pathfinder” projects announced by Prime Minister Modi (India) and President Obama in January 2015 under the Defense Technology and Trade Initiative.

About Arotech’s Power Systems Division
Arotech’s Power Systems Division is a leading provider of primary and rechargeable batteries and chargers for defense and other military applications and of electronic components and subsystems primarily for military, aerospace and industrial customers. Arotech develops and produces high power zinc-air batteries and is believed to be the sole supplier of this technology to the U.S. military. In addition, Arotech develops high-end primary and secondary batteries and associated chargers, as well as (i) hybrid power generation systems, (ii) smart power subsystems for military vehicles and dismounted applications, and (iii) aircraft and missile systems support for cutting-edge weapons and communications technologies, and has vast experience in working with government agencies, the military and large corporations. The Power Systems Division consists of Electric Fuel Battery Corporation (www.efbpower.com), Epsilor-Electric Fuel Ltd. (www.epsilor.com; www.electric-fuel.com), and UEC Electronics, LLC (www.uec-electronics.com).

About Arotech Corporation

Arotech Corporation is a leading provider of quality defense and security products for the military, law enforcement and homeland security markets, including multimedia interactive simulators/trainers and advanced zinc-air and lithium batteries and chargers. Arotech operates two major business divisions: Training and Simulation, and Power Systems.

Arotech is incorporated in Delaware, with corporate offices in Ann Arbor, Michigan, and research, development and production subsidiaries in Michigan, South Carolina, and Israel. For more information on Arotech, please visit Arotech’s website at www.arotech.com.

U.S. Power Systems Division Contact:

Nancy Straight
Business Development Manager
843-552-8682
nancystraight@uec-electronics.com

Arotech Investor Relations Contacts:

Brett Maas / Rob Fink
Hayden IR
(646) 536.7331 / (646) 415.8972
ARTX@haydenir.com

Arotech Training and Simulation Division Announces IDIQ Award Valued at up to $40 Million

ANN ARBOR, Mich., April 20, 2016  — Arotech Corporation [Nasdaq GM: ARTX] announced that its Training and Simulation Division (ATSD) has received an Indefinite Delivery Indefinite Quantity (IDIQ) award with a potential value of up to $40M for its MILO Range Training Systems’ simulator products. The multiple-award contract is for the provision of law enforcement training simulators and related equipment and services to the U.S. Department of State in support of its Bureau of International Narcotics and Law Enforcement Affairs (INL) training mission. INL works to keep Americans safe at home by countering international crime, illegal drugs, and instability abroad. INL provides training and assistance in all aspects of police, corrections and justice systems tailored to the specific environment, legal framework, and identified requirements of each partner nation.  MILO Range Training Systems was one of two awardees following a competitive full and open solicitation.  The Period of performance is five years and includes MILO Range Theater multi-screen and MILO Range portable solutions.

“We are thrilled with this award, which solidifies our long standing position as a supplier to the Department of State for our award winning MILO Range Training Systems,” commented Robert McCue, MILO Range Training Systems General Manager. “This highly competitive procurement further validates our position as a global leader in the international law enforcement judgmental skills simulator market, and provides a streamlined acquisition process to deliver this important training capability to the various organizations supported by the U.S. Department of State.”

About Arotech’s Training and Simulation Division

Arotech’s Training and Simulation Division (ATSD) provides world-class simulation based solutions. ATSD develops, manufactures, and markets advanced high-tech multimedia and interactive digital solutions for engineering, use-of-force, and operator training simulations for military, law enforcement, security, municipal and private industry personnel. The division’s fully interactive operator training systems feature state-of-the-art vehicle simulator technology enabling training in situation awareness, risk analysis and decision-making, emergency reaction and avoidance procedures, conscientious equipment operation, and crew coordination. The division’s use-of-force training products and services allow organizations to train their personnel in safe, productive, and realistic environments. The division supplies pilot decision-making support software for the F-15, F-16, F-18, F-22, and F-35 aircraft, simulation models for the ACMI/TACTS air combat training ranges, and Air-Refueling Boom Arm simulators. The division also provides consulting and developmental support for engineering and research simulation solutions.

Arotech’s Training and Simulation Division consists of FAAC Incorporated (www.faac.com), MILO Range Training Systems (www.milorange.com), and Realtime Technologies (www.simcreator.com).

About Arotech Corporation

Arotech Corporation is a leading provider of quality defense and security products for the military, law enforcement and homeland security markets, including multimedia interactive simulators/trainers and advanced zinc-air and lithium batteries and chargers. Arotech operates two major business divisions: Training and Simulation, and Power Systems.

Arotech is incorporated in Delaware, with corporate offices in Ann Arbor, Michigan, and research, development and production subsidiaries in Michigan, South Carolina, and Israel. For more information on Arotech, please visit Arotech’s website at www.arotech.com.

Investor Relations Contacts:

Brett Maas / Rob Fink
Hayden IR
(646) 536.7331 / (646) 415.8972
ARTX@haydenir.com

Except for the historical information herein, the matters discussed in this news release include forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, readers are cautioned not to place undue reliance on these forward-looking statements, as they are subject to various risks and uncertainties that may cause actual results to vary materially. These risks and uncertainties include, but are not limited to, risks relating to: product and technology development; the uncertainty of the market for Arotech’s products; changing economic conditions; delay, cancellation or non-renewal, in whole or in part, of contracts or of purchase orders (including as a result of budgetary cuts resulting from automatic sequestration under the Budget Control Act of 2011); and other risk factors detailed in Arotech’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and other filings with the Securities and Exchange Commission. Arotech assumes no obligation to update the information in this release. Reference to the Company’s website above does not constitute incorporation of any of the information thereon into this press release.

Wednesday, April 20th, 2016 Uncategorized Comments Off on (ARTX) Wins Marine Corps Contract, $40 Million IDIQ Award

(OCLS) Receives U.S. FDA Approval for Lasercyn™

PETALUMA, Calif., April 20, 2016 — Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new Microcyn®-based Lasercyn™ Gel.  Under the supervision of a healthcare professional, Lasercyn Gel is intended for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. Lasercyn may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.

Dr. Michael Gold, board-certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center, and Tennessee Clinical Research Center, all located in Nashville, Tennessee, commented, “Lasercyn is a promising new tool for all aesthetic dermatologists who are looking to better manage post-laser itch and pain associated with laser skin resurfacing, along with enhanced healing. In our clinical testing of Lasercyn to date, we have seen dramatically improved outcomes with quicker healing times and less patient discomfort when Lasercyn is added to the post-procedure management protocol.”

Oculus will begin marketing Lasercyn via its own U.S. dermatology sales team beginning in the summer of 2016.

About Laser Skin Resurfacing
According to the Clinical, Cosmetic and Investigational Dermatology Journal, medical and aesthetic skin procedures have seen a steady surge within the last decade, and a higher demand for skin rejuvenation practices. In 2013 in the United States, dermatologic surgeons performed over 9.5 million treatments, an almost 22% increase from the previous year, with a rising number of treatments involving skin resurfacing in the areas of laser/light/energy-based procedures (2.25 million), chemical peels (1.1 million), and microdermabrasion (974,000).

Laser skin resurfacing, also known as a laser peel, laser vaporization and lasabrasion, can reduce facial wrinkles, scars and blemishes. Newer laser technologies provide surgeons with a new level of control in laser surfacing, permitting extreme precision, especially in delicate areas.  The laser beam used in laser resurfacing will remove outer layer of skin, called the epidermis. It simultaneously heats the underlying skin, called the dermis. This action works to stimulate growth of new collagen fibers. As the treated area heals, the new skin that forms is smoother and firmer.

Common side effects include redness of the skin, swelling of the treated area, itch, pain and moderate irritation similar to the feeling produced by a mild sunburn.

About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.

Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “marketing” and “looking,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s common stock and warrants may be delisted from NASDAQ, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the year ended March 30, 2015. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Oculus®, Microcyn® Technology and Lasercyn™ are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Oculus Innovative Sciences, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@oculusis.com
Wednesday, April 20th, 2016 Uncategorized Comments Off on (OCLS) Receives U.S. FDA Approval for Lasercyn™

(UNXL) Wins Fourth 2016 Program From Tier 1 US PC Manufacturer

XTouch™ and Diamond Guard™ chosen to enhance stylus performance

SANTA CLARA, Calif., April 20, 2016  UniPixel, Inc. (NASDAQ: UNXL), a provider of advanced touch solutions to the touchscreen and flexible electronics markets, today announced a new design win from a leading U.S. PC manufacturer for a 13.3-inch laptop computer. The new laptop will feature UniPixel’s XTouch touch screen sensors with Diamond Guard hardcoat in an advanced laptop design. This program represents the fourth win in 2016 with this customer and further expands our business footprint with this leading manufacturer.

Jeff Hawthorne, president and chief executive officer of UniPixel, said, “We now have two major customers that have awarded us four programs each thus far in 2016. We are gratified that these existing customers, both industry leaders, value our technology enough to award us multiple programs. The increasing acceptance of our products not only demonstrates the performance attributes of our highly differentiated products, but it also validates our manufacturing capabilities to support the needs of our customers to create the leading-edge devices that their end-user consumers demand.”

UniPixel’s highly responsive XTouch touchscreen sensor technology with its outstanding finger-touch and capacitive stylus performance, in conjunction with the company’s Diamond Guard hardcoat technology which reduces overall cost and weight, will enable this manufacturer to produce a superior new 13.3-inch laptop computer. Volume production for this program is expected to commence during the fourth calendar quarter of 2016.

About UniPixel
UniPixel, Inc. (NASDAQ: UNXL) develops and markets Performance Engineered Films for the touch screen and flexible electronics markets. The company’s roll-to-roll electronics manufacturing process patterns fine line conductive elements on thin films. The company markets its technologies for touch panel sensor, cover glass replacement, and protective cover film applications under the XTouch™ and Diamond Guard™ brands. For further information, visit www.unipixel.com.

Forward-looking Statements
All statements in this news release that are not based on historical fact are “forward-looking statements” within the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended including the statement that UniPixel’s integrated technologies are expected to provide enhanced yields at a lower cost, thereby expanding UniPixel’s competitiveness in the touch screen market.  While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015. UniPixel operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the company’s Annual Report on Form 10-K, quarterly reports on Form 10-Q and Current Reports on Form 8-K.

Trademarks in this release are the property of their respective owners

Contact:
Joe Diaz, Robert Blum, Joe Dorame
Lytham Partners, LLC
602-889-9700
unxl@lythampartners.com

Wednesday, April 20th, 2016 Uncategorized Comments Off on (UNXL) Wins Fourth 2016 Program From Tier 1 US PC Manufacturer

(SGYP) Acceptance of NDA for Plecanatide for Plecanatide

PDUFA target action date of January 29, 2017

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the U.S. Food and Drug Administration (FDA) has determined that the company’s New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.

“This is a transformative milestone for our company and reflects our relentless commitment to bringing meaningful treatment options to patients suffering from GI diseases,” said Gary S. Jacob, Chairman and Chief Executive Officer of Synergy Pharmaceuticals. “If approved, we believe plecanatide will become an important new treatment option that will benefit patients with CIC. I want to thank the Synergy employees and outside consultants working on the CIC NDA for their hard work and dedication which contributed to this important milestone.”

The NDA for plecanatide is supported by two double-blind placebo-controlled phase 3 trials and one open-label long term safety study. A total of more than 2,700 patients with CIC received a once-daily dose of either plecanatide or placebo across the two placebo-controlled trials. Additionally, over 3,500 patients were exposed to plecanatide in the CIC clinical development program.

About Plecanatide

Plecanatide is our first uroguanylin analog currently being evaluated for use as a once-daily tablet for the treatment of two functional GI disorders, CIC and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally similar to uroguanylin with the exception of a single amino acid change. Plecanatide is designed to replicate the function of uroguanylin, a naturally occurring GI peptide, by working locally in the upper GI tract to stimulate digestive fluid movement and support regular bowel function. In 2015, we announced positive phase 3 data with plecanatide in two pivotal CIC clinical trials and on January 29, 2016 the company filed its first NDA for plecanatide in CIC. We presently have two ongoing phase 3 clinical trials with plecanatide in IBS-C and intend to file our second NDA in IBS-C by the end of this year. We expect top-line data results from both pivotal IBS-C trials in the third quarter of this year.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development and commercialization of novel GI therapies. Our proprietary GI platform is based on uroguanylin and includes two lead product candidates – plecanatide and dolcanatide. Dolcanatide is our second uroguanylin analog currently being explored for inflammatory bowel disease. Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine. In January 2016, we announced positive data with dolcanatide in a phase 1b trial with ulcerative colitis patients. For more information, please visit www.synergypharma.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward- looking words such as “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on Synergy’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Synergy’s Form 10-K for the year ended December 31, 2015 and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Synergy does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

 

Synergy Pharmaceuticals:
Gem Hopkins, 212-584-7610
VP, Investor Relations and Corporate Communications
ghopkins@synergypharma.com

Tuesday, April 19th, 2016 Uncategorized Comments Off on (SGYP) Acceptance of NDA for Plecanatide for Plecanatide

(TGEN) Schedules Earnings Release and Conference Call for Q1 2016 Results

WALTHAM, Mass., April 19, 2016  — Tecogen® Inc. (NASDAQ: TGEN) will release its financial results for the first quarter of 2016 on Wednesday, May 11, 2016. The earnings press release and supplemental earnings call slides will be available on the Company website at www.Tecogen.com in the “Investor Relations” section under “About Us.” Members of Tecogen’s senior management will hold a conference call and webcast on the same day at 11:00 AM Eastern Time to discuss the company’s first quarter financial performance.

The conference call will be available live via telephone and webcast. To listen to the audio portion, dial (888) 349-0103 within the U.S., (855) 669-9657 from Canada, or + (412) 902-0129 from other international locations. Participants should ask to be joined to the Tecogen Inc. earnings call. Please begin dialing at least 10 minutes before the scheduled starting time. Alternately, to register for and listen to the webcast, go to http://investors.tecogen.com/webcast.

The earnings conference call will be recorded and available for playback one hour after the end of the call through Wednesday, May 18th, 2016.  To listen to the playback, dial (877) 344 7529 within the U.S., (855) 669-9658 from Canada, or (412) 317-0088 outside the U.S. and use Replay Access Code 10084852. Following the call, the webcast will be archived for 30 days.

About Tecogen
Tecogen manufactures, installs, and maintains high efficiency, ultra-clean, combined heat and power products including natural gas engine-driven cogeneration, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company is known for cost efficient, environmentally friendly and reliable products for energy production that, through patented technology, nearly eliminate criteria pollutants and significantly reduce a customer’s carbon footprint.

In business for over 20 years, Tecogen has shipped more than 2,300 units, supported by an established network of engineering, sales, and service personnel across the United States. For more information, please visit www.tecogen.com or follow us on Twitter, Facebook, and LinkedIn.

Tecogen, InVerde, Ilios, Tecochill, Ultera, and e+, are registered trademarks of Tecogen Inc.

Tecogen Media & Investor Relations Contact Information:
Ariel F. Babcock, CFA John N. Hatsopoulos
P: (781) 466-6413 P: (781) 622-1120
E: Ariel.Babcock@tecogen.com E: John.Hatsopoulos@tecogen.com
Tuesday, April 19th, 2016 Uncategorized Comments Off on (TGEN) Schedules Earnings Release and Conference Call for Q1 2016 Results

(VRML) Announces Publication of First OVA1® Clinical Utility Study

Nearly all of the patients who had primary ovarian malignancies were appropriately referred to gynecologic oncologists, highlighting the clinical utility of OVA1

AUSTIN, Texas, April 19, 2016  — Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the publication of the first clinical utility data demonstrating that identification of high-risk patients using OVA1 prior to surgery resulted in referral of nearly all patients who had primary ovarian malignancies to gynecologic oncologists.  The study, titled “The clinical utility of an elevated-risk multivariate index assay score measured by pre-surgical involvement of gynecologic oncologists in the management of ovarian cancer,” to be published in the peer-reviewed journal Current Medical Research & Opinion (CMRO), is now available online as a pre-print (DOI: 10.1080/03007995.2016.1176014).

Dr. Ramez Eskander, first author and faculty member at UC Irvine’s Division of Gynecologic Oncology in Orange, California, stated, “This study documents the first peer-reviewed evidence on how OVA1 results affect real-world patient care. Approximately 80% of patients with a high-risk OVA1 result were referred to or consulted with a gynecologic oncologist, providing an opportunity for critical pre-surgical input to patient care. Even more important, 100% specialist involvement was found in the 65 primary ovarian cancer cases, with 94% of these surgeries being performed by a gynecologic oncologist.”

Vermillion’s Chief Medical Officer and co-author of the study, Dr. Judith Wolf, added, “An important opportunity to improve survival is lost when initial ovarian cancer surgery and treatment is not performed by a trained specialist. Unfortunately, many women fail to receive this care today, in part due to less sensitive and more subjective methods commonly used to assess ovarian cancer risk prior to surgery. Our clinical utility study of high-risk OVA1 results represents an important step in providing women with highly effective access to specialist care for ovarian cancer.”

The study surveyed physicians with frequent OVA1 use, and identified 122 patients who underwent surgery for a pelvic mass after a high-risk OVA1 score was reported. Of these, 65 had a primary ovarian malignancy, while the remainder were benign or had a metastatic cancer of non-ovarian origin. Pre-surgical involvement of a gynecologic oncologist was documented, including referral, consultation or availability on stand-by; and the specialty of the surgeon who performed the adnexal surgery was also recorded. Of the 4 patients whose surgery was not performed by a gynecologic oncologist, 2 required re-operation for complete staging by a gynecologic oncologist. In comparison, none of the 61 ovarian cancers that were operated on by a gynecologic oncologist required restaging. According to the National Academy of Medicine’s 2016 report, Ovarian Cancers: Evolving Paradigms in Research and Care, re-operations are common after non-specialists operate on ovarian cancer, and may result in delayed treatment, higher costs and inferior outcomes compared with ‘first time right’ surgery by a gynecologic oncologist.

Clinical utility of low-risk OVA1 results may be the subject of a future publication.

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women conquer serious diseases.  The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

About OVA1® and Overa™

  • OVA1 is a proprietary FDA-cleared blood test to help physicians assess the risk of ovarian cancer prior to surgery and as a result provide more effective referral of high risk patients to a specialist (gynecologic oncologist) for surgical treatment
  • The OvaCalc® proprietary algorithm combines five biomarker results into a single numerical “risk score” that stratifies patients into “higher risk” and “lower risk” when combined with clinical assessment
  • In two pivotal clinical trials, OVA1 plus clinical impression detected 96% of all malignancies vs. 75% for clinical impression alone (CI). As a result, false negatives were reduced from 25% for CI, to 4% with OVA1 plus CI, a reduction of 83%
  • In a study focused on early-stage cancer detection, 31% of cases were missed by clinical impression alone. This was reduced to 5% when OVA1 was added to clinical impression, a reduction of 85%
  • Overa, cleared by FDA on March 18, 2016, measures the levels of five proteins found in the blood and then uses a second-generation OvaCalc® algorithm to stratify risk. A woman’s risk of cancer is measured by using a 0-10 scale with a single cut-off point of 5 eliminating the ambiguity in determining menopausal status. A high Overa score is not a diagnosis of cancer, rather it indicates an increased risk of malignancy when used as intended.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant a number of risks and uncertainties, including with respect to future publications.  Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion’s expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ from those projected in such forward-looking statements include but are not limited to factors that are described in Vermillion’s Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com
Tuesday, April 19th, 2016 Uncategorized Comments Off on (VRML) Announces Publication of First OVA1® Clinical Utility Study

(PLG) Reports 13% Increase in F Zone Grade, 89% Increase in Indicated Resources

Waterberg Pre-Feasibility Study Continues for a Decline Tunnel Access and a Fully Mechanized Mine Plan

VANCOUVER, BRITISH COLUMBIA and JOHANNESBURG, SOUTH AFRICA–(April 19, 2016) – Platinum Group Metals Ltd. (TSX:PTM)(NYSE MKT:PLG) (“Platinum Group” or the “Company”) reports increased grade and a significant increase in indicated ounces in an updated independent resource estimate for platinum, palladium, rhodium and gold (“4E”) on the 58.65% owned Waterberg Joint Venture, located on the North Limb of the Bushveld Complex.

Mineral resources in the “T” and “F” zones at Waterberg (100% project basis) have increased to an estimated 23.894 million ounces 4E in the indicated category plus 11.710 million ounces 4E in the inferred category:

  • Indicated 209.559 million tonnes grading 3.55 g/t 4E (1.07 g/t Pt, 2.19 g/t Pd, 0.26 g/t Au, 0.03 g/t Rh, 2.5 g/t cut-off)
  • Inferred 105.918 million tonnes grading 3.44 g/t 4E (1.04 g/t Pt, 2.09 g/t Pd, 0.28 g/t Au, 0.03 g/t Rh, 2.5 g/t cut-off)

R. Michael Jones, P.Eng., President, CEO and co-founder of Platinum Group Metals said “We have been very successful in almost doubling indicated resources to 24 million ounces. Waterberg is an extraordinary deposit that we have not yet found the limits to. Starting at 140 meters from surface, with zones 3 to 70 meters thick and an overall proven strike length of 13 km so far, Waterberg stands apart from conventional platinum mines in South Africa. The increased F zone grade combined with improved deposit definition allows for the targeting of best grade thickness in early mine scheduling, which is changing the project significantly from our earlier engineering work. We are looking at a series of adjacent mine plans, each at the scale of a typical stand-alone mine, to be prioritized and processed at a single central plant.”

The resource estimate includes sampling and data from 294 diamond drill boreholes with 459 deflections for a total of 584 intersections into the deposit from a total of approximately 293,538 meters of core drilling. The deposit model is a kriged estimate from Data Mine geological wireframes.

The deposit is 13 km long, open along strike and begins from 140 meters deep. The deposit is known to continue down dip below the arbitrary 1,250 meter cut off depth applied to the deposit for resource estimation purposes. Minimum mineralized thickness is 3 meters and the maximum is 70 meters. Drilling is continuing at Waterberg and the deposit is still open for expansion. Assays for shallow Super F zones at 180 meters to 300 meters from surface are outstanding. Deeper “Super T” targets are being drilled now. The most recent intercept in the “Super T” zone is 7.76 meters grading 6.14 g/t 4E and the deposit in the area of this hole is open for expansion.

Pre-Feasibility Update

The Pre-Feasibility Study is on track with this resource update to be completed at the end of July 2016. The engineering work is being completed by project teams from Worley Parsons (Advisian) and DRA. Both firms are experienced global, independent, mining engineering firms. Optimization of mine plans in five target zones (3 on the Super F zone and 2 on the T and Super T zones) is underway. Metallurgical test work and concentrate marketing discussions are in progress. Indications from metallurgical test work are that a good grade concentrate with similar base metals content to desirable Merensky concentrate, with no penalty chrome, can be produced. Site infrastructure work for power and water designs and costing are also well advanced.

JOGMEC Agreement and Funding

Drilling and engineering work is being funded 100% at this time by the Japan Oil, Gas and Metals National Corporation (“JOGMEC”) under a US$ 20 million firm commitment to the Joint Venture. A budget for US$ 6 million for April 1, 2016 to March 31, 2017 set out under the JOGMEC agreement commitment is in progress. The Company may accelerate expenditure levels at Waterberg if it has sufficient working capital on hand to do so. JOGMEC continues to be an excellent active technical partner with its geological and metallurgical in house expertise.

Mineral Resource Details

F Zone
Cut-off Tonnage Grade Metal
3PGE+Au Pt Pd Au Rh 3PGE+Au 3PGE +Au
g/t Mt g/t g/t g/t g/t g/t Kg Moz
Indicated
2.00 281.184 0.91 1.94 0.15 0.03 3.03 851 988 27.392
2.50 179.325 1.05 2.23 0.18 0.03 3.49 625 844 20.121
3.00 110.863 1.19 2.52 0.20 0.04 3.95 437 909 14.079
Inferred
2.00 177.961 0.83 1.77 0.13 0.03 2.76 491 183 15.792
2.50 84.722 1.01 2.14 0.17 0.03 3.35 283 819 9.125
3.00 43.153 1.19 2.53 0.20 0.04 3.96 170 886 5.494
T Zone
Cut-off Tonnage Grade Metal
2PGE+Au Pt Pd Au Rh 2PGE+Au 2PGE +Au
g/t Mt g/t g/t g/t g/t g/t Kg Moz
Indicated
2.00 36.308 1.08 1.81 0.72 3.61 131 162 4.217
2.50 30.234 1.16 1.94 0.78 3.88 117 363 3.773
3.00 22.330 1.28 2.14 0.86 4.28 95 640 3.075
Inferred
2.00 23.314 1.10 1.83 0.73 3.66 85 240 2.741
2.50 21.196 1.14 1.90 0.76 3.79 80 394 2.585
3.00 14.497 1.28 2.14 0.86 4.28 62082 1.996
Waterberg Total
Cut-off Tonnage Grade Metal
3PGE+Au Pt Pd Au Rh 3PGE+Au 3PGE +Au
g/t Mt g/t g/t g/t g/t g/t Kg Moz
Indicated
2.00 317.492 0.93 1.92 0.22 0.03 3.10 983 150 31.609
2.50 209.559 1.07 2.19 0.26 0.03 3.55 743 207 23.894
3.00 133.193 1.21 2.46 0.31 0.03 4.01 533 549 17.154
Inferred
2.00 201.275 0.85 1.77 0.21 0.03 2.86 576 423 18.533
2.50 105.918 1.04 2.09 0.28 0.03 3.44 364 213 11.710
3.00 57.650 1.21 2.43 0.37 0.03 4.04 232 968 7.490

1. Mineral resources are classified in accordance with the SAMREC standards. There are certain differences with the “CIM Standards on Mineral Resources and Reserves”; however, in this case the Company and the QP believe the differences are not material and the standards may be considered the same. Mineral resources do not have demonstrated economic viability and inferred resources have a high degree of uncertainty. Mineral resources might never be upgraded or converted to reserves.

2. Mineral resources are provided on a 100% project basis. Inferred and indicated categories are separate. The estimates have an effective date of April 18th 2016. Tables may not add perfectly due to rounding.

3. A cut-off grade of 2.5 g/t 3E (platinum, palladium and gold) for the T zone and 2.5 g/t 4E for the F zone is applied to the selected base case mineral resources. Prior to July 20, 2015, a 2 g/t cut-off was applied to resource estimates. For comparison with earlier resources a 2 g/t cut-off on the updated resource model is presented above. Cut-off grades of 3.0 g/t 4E are also presented as certain mining plans in early years may apply higher cut-offs for the Pre-Feasibility Study.

4. Cut off for the T and the F zones considered costs, smelter discounts, concentrator recoveries from the previous and ongoing engineering work completed on the property by the Company and its independent engineers. Spot and three year trailing average prices and exchange rates are considered for the cut-off considerations. Metallurgical work indicates that an economically attractive concentrate can be produced from standard flotation methods.

5. Mineral resources were completed by Charles Muller of CJM Consulting and a NI 43-101 technical report for the mineral resources reported herein, effective April 18, 2016, will be filed on SEDAR within 45 days of today’s date.

6. Mineral resources were estimated using Kriging methods for geological domains created in Datamine Studio3 from 262 mother holes and 322 deflections in mineralization. A process of geological modelling and creation of grade shells using indicating kriging was completed in the estimation process.

7. The estimation of mineral resources have taken into account environmental, permitting, legal, title, taxation, socio-economic, marketing and political factors. The mineral resources may be materially affected by metals prices, exchange rates, labour costs, electricity supply issues or many other factors detailed in the Company’s Annual Information Form.

8. The following prices based on an approximate recent 3 year trailing average in accordance with U.S. Securities and Exchange Commission (“SEC”) guidance was used for the assessment of Resources; USD Pt 1,243/oz, Pd 720/oz, Au 1,238/oz, Rh 1,015/oz – see Cautionary Note.

9. Estimated grades and quantities for by-products will be included in recoverable metals and estimates in the on-going pre-feasibility work. Copper and Nickel are the main value by-products recoverable by flotation and for indicated resources are estimated at 0.18% copper and 0.10% nickel in the T zone 0.07% copper and 0.16% nickel in the F zone.

CIM guideline on resource classification:

An Inferred Mineral Resource is that part of a mineral resource for which quantity and grade or quality are estimated on the basis of limited geological evidence and sampling. Geological evidence is sufficient to imply but not verify geological and grade or quality continuity.

An Inferred Mineral Resource has a lower level of confidence than that applying to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that the majority of Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration.

An Indicated Mineral Resource is that part of a mineral resource for which quantity, grade or quality, densities, shape and physical characteristics are estimated with sufficient confidence to allow the application of Modifying Factors in sufficient detail to support mine planning and evaluation of the economic viability of the deposit.

Geological evidence is derived from adequately detailed and reliable exploration, sampling and testing and is sufficient to assume geological and grade or quality continuity between points of observation.

An Indicated Mineral Resource has a lower level of confidence than that applying to a Measured Resource.

Qualified Person Data Verification and Quality Control and Assurance

Scientific and Technical Information in this Press Release related to mineral resources has been reviewed and approved by Charles J Muller, (BScHons) Pr Sci Nat (Reg. No 400201/04), an independent consulting geologist and resource estimator of CJM Consulting, an independent qualified person as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“N1 43-101”). He has verified the data by reviewing the detailed assay and geological information and metallurgical work on the Waterberg deposit and he visited the property in July 2015. He is satisfied that the data is appropriate for the resource estimate by reviewing the core, assay certificates and quality control information as well as reviewing the procedures on sampling, chain of custody and data base records of the Platinum Group exploration team.

Base metals and other major elements were determined by multi acid digestion with Inductively Coupled Plasma (“ICP”) finish and PGEs were determined by conventional fire assay and ICP finish. Setpoint Laboratories is an experienced ISO 17025 SANAS accredited laboratory in assaying and have utilized a standard quality control system including the use of standards. Platinum Group utilized a well-documented system of inserting blanks and standards into the assay stream and has a strict chain of custody and independent lab re-check system for quality control.

This press release has been reviewed and approved by R. Michael Jones, P.Eng., a non-independent Qualified Person and the CEO of the Company.

A report with respect to the technical information contained here is planned to be filed on www.sedar.com within 45 days.

On behalf of the Board of Platinum Group Metals Ltd.

R. Michael Jones, CEO and Co-founder

Disclosure

The Toronto Stock Exchange and the NYSE MKT LLC have not reviewed and do not accept responsibility for the accuracy or adequacy of this news release, which has been prepared by management.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. securities laws (“forward-looking statements”). Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, plans, postulate and similar expressions, or are those, which, by their nature, refer to future events. All statements that are not statements of historical fact are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding all technical details of the updated mineral resources. A shortage of working capital may materially affect the Company ability to complete its plans. Although the Company believes the forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, variations in market conditions; the nature, quality and quantity of any mineral deposits that may be located; metal prices; other prices and costs; currency exchange rates; the Company’s ability to obtain any necessary permits, consents or authorizations required for its activities; the Company’s ability to access further funding and produce minerals from its properties successfully or profitably, to continue its projected growth, or to be fully able to implement its business strategies and other risk factors described in the Company’s Form 40-F annual report, annual information form and other filings with the SEC and Canadian securities regulators, which may be viewed at www.sec.gov and www.sedar.com, respectively.

Cautionary Note to U.S. and other Investors

Estimates of mineralization and other technical information included or referenced in this press release have been prepared in accordance with NI 43-101. The definitions of proven and probable reserves used in NI 43-101 differ from the definitions in SEC Industry Guide 7. Under SEC Industry Guide 7 standards, a “final” or “bankable” feasibility study is required to report reserves, the three-year historical average price is used in any reserve or cash flow analysis to designate reserves and the primary environmental analysis or report must be filed with the appropriate governmental authority. As a result, the reserves reported by the Company in accordance with NI 43-101 may not qualify as “reserves” under SEC standards. In addition, the terms “mineral resource”, “measured mineral resource”, “indicated mineral resource” and “inferred mineral resource” are defined in and required to be disclosed by NI 43-101; however, these terms are not defined terms under SEC Industry Guide 7 and normally are not permitted to be used in reports and registration statements filed with the SEC. Mineral resources that are not mineral reserves do not have demonstrated economic viability. Investors are cautioned not to assume that any part or all of the mineral deposits in these categories will ever be converted into reserves. “inferred mineral resources” have a great amount of uncertainty as to their existence, and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to a higher category. Under Canadian securities laws, estimates of inferred mineral resources may not form the basis of feasibility or pre-feasibility studies, except in rare cases. Additionally, disclosure of “contained ounces” in a resource is permitted disclosure under Canadian securities laws; however, the SEC normally only permits issuers to report mineralization that does not constitute “reserves” by SEC standards as in place tonnage and grade without reference to unit measurements. Accordingly, information contained or referenced in this press release containing descriptions of the Company’s mineral deposits may not be comparable to similar information made public by U.S. companies subject to the reporting and disclosure requirements of United States federal securities laws and the rules and regulations thereunder.

R. Michael Jones, President & CEO
or Kris Begic, VP, Corporate Development
Platinum Group Metals Ltd., Vancouver
(604) 899-5450 / Toll Free: (866) 899-5450
www.platinumgroupmetals.net

Tuesday, April 19th, 2016 Uncategorized Comments Off on (PLG) Reports 13% Increase in F Zone Grade, 89% Increase in Indicated Resources

(EXPI) MissionIR Exclusive Audio Interview With CEO Glenn Sanford

ATLANTA, GA–(Apr 19, 2016) –  MissionIR today announces the online availability of its interview with Glenn Sanford, CEO and founder of eXp Realty International Corp. (OTCQB: EXPI), which, as previously announced, is changing its name to eXp World Holdings, Inc. to reflect its achievements and growth initiatives discussed in the interview. The interview can be heard at http://www.QualityStocks.net/interview-expi.php.

EXPI is the holding company for several businesses, including eXp Realty LLC, the Agent-Owned Cloud Brokerage™, a full-service real estate brokerage utilizing a 3D, fully immersive, cloud office environment that provides around-the-clock access to collaborative tools, training, and socialization for real estate brokers and agents.

Sanford begins the interview with further insight into this structure, the company’s broader business strategy in the residential real estate space, and its growing presence in 35 U.S. states and two Canadian provinces.

Much of this growth is largely attributed to the company’s revenue sharing program and innovative virtual platform, which replaces the need for a traditional real estate office. By reducing its bricks and mortar footprint, EXPI is able to share its revenues with agents and brokers who contribute to corporate growth.

As of March 31, 2016, EXPI had grown its agent base to more than 1,100 members, representing 100% agent growth in a single year, along with correlating revenue and cash flow.

“Agents and brokers have a great split, because obviously we don’t have the overhead. But we also pass on the different initiatives – revenue share being one of them, and the other one being a stock ownership initiative … that’s really created a big catalyst for growth,” says Sanford.

Another stimulant for EXPI’s growth is a strong management team. Sanford first describes his extensive background as a long-time entrepreneur before describing the skills and experience of several other powerhouse members of the company’s leadership.

After recapping several of EXPI’s 2015 milestones, Sanford wraps up the interview by discussing the company’s goals for 2016.

“The biggest goal is just really to build infrastructure to support the growth … that’s a lot of people to assimilate in the organization and make part of the culture of the organization, and then all the tools and systems that need to be in place to support all of them,” he says. “If we keep on doing what we’re doing … we should easily end up in excess of 1,800, maybe 2,000 agents this year … if we hit those numbers then we really, in 2017, should be in the 3,500 agent range. If you work that into the revenue side of it … this year we should do in excess of $40 million in revenue … so we’re really excited about the growth.”

About eXp World Holdings, Inc.

eXp World Holdings, Inc. is the holding company for a number of companies most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™ as a full-service real estate brokerage providing 24/7 access to collaborative tools, training, and socialization for real estate brokers and agents through its 3-D, fully-immersive, cloud office environment. eXp Realty, LLC and eXp Realty of Canada, Inc. also feature an aggressive revenue sharing program that pays agents a percentage of gross commission income earned by fellow real estate professionals who they attract into the Company.

eXp World Holdings, Inc. also owns 90.5% of First Cloud Mortgage, Inc. a Delaware corporation launched in 2015 and now licensed to originate mortgages in Arizona, California, New Mexico and Texas.

For more information, visit www.exprealty.com or www.investors.exprealty.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Trade & Media
Jason Gesing
President
617-970-8518
Email Contact
www.eXpRealty.com

Investor Relations
Mission Investor Relations
Atlanta, Georgia
404-941-8975
Email Contact
http://www.MissionIR.com

Tuesday, April 19th, 2016 Uncategorized Comments Off on (EXPI) MissionIR Exclusive Audio Interview With CEO Glenn Sanford

(AMDA) Signs Exclusive Chinese Silicon Nitride Distribution Agreement

10-Year Exclusive Agreement to Represent Significant Global Sales Expansion and Minimum Purchase Requirements

SALT LAKE CITY, UT–(Apr 18, 2016) – Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce a partnership with Shandong Weigao Orthopedic Device Company Limited (“Weigao Orthopedic”), a subsidiary of Shandong Weigao Group Medical Polymer Company Limited (HKSE: 1066), a medical device company in China specializing in the R&D, production and sale of spine, trauma and joint orthopedic implants.

Under the distribution agreement, Weigao Orthopedic will have exclusive rights for the sale, marketing and distribution of Amedica-branded silicon nitride spinal implants in the People’s Republic of China, and will abide by minimum annual purchase requirements in Year 1 of 20,000 units, growing annually to 50,000 units in Year 6, following regulatory clearance by the China Food and Drug Administration (CFDA). Weigao Orthopedic will leverage its expertise in acquiring CFDA clearance of medical devices, in order to accelerate Chinese clearance of Amedica’s products.

“With more than 50,000 minimum unit sales to occur within the first two years following CFDA clearance, this agreement far surpasses total silicon nitride unit sales to-date, and marks a momentous time for Amedica,” said Dr. Sonny Bal, Chairman and Chief Executive Officer. “This partnership with Weigao Orthopedic allows us to significantly increase our global sales footprint with a large-scale distribution partner who is familiar with the Chinese regulatory landscape. Weigao Orthopedic’s expertise in sales and distribution is an excellent fit for our innovative silicon nitride technology platform. We look forward to this key strategic partnership to distribute our silicon nitride technology into Asian markets that are particularly receptive to bioceramic implants.”

“We are very pleased with this exclusive distributor partnership as we plan to leverage the Amedica brand to offer a truly differentiated product to our broad network of hospitals and medical units in China,” stated Mr. Gong Jianbo, Chief Executive Officer and Executive Director of Weigao Orthopedic. “We expect the combination of this technically advanced biomaterial with our well-established network to quickly gain significant market share. We also look forward to expanding our partnership beyond spine products and into hip and knee applications. Weigao Orthopedic is well positioned to facilitate the approval and commercial launch of Amedica’s silicon nitride spinal fusion devices in one of the world’s largest healthcare markets.”

About Amedica Corporation
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Shandong Weigao Group
Shandong Weigao Group and its subsidiaries are principally engaged in the research and development, production and sale of single-use medical devices. The Group has a wide range of products, which includes consumables, orthopedic materials, and blood purification consumables and equipment. The Group’s main production facilities are situated in Weihai, Shandong Province.

The Group is incorporated in the People’s Republic of China and has an extensive sales network comprising 28 sales offices, 34 customer liaison centers and 222 cities with sales representatives. Shandong Weigao Group has a total customer base of 5,298 (including 3,132 hospitals, 414 blood stations, 643 other medical units and 1,109 distributors).

For more information on Shandong Weigao Group, please visit http://en.weigaogroup.com.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica’s future performance, business operations and acceptance of its technology platform. Statements relating to Amedica’s expectation that the relationship with Weigao will expand the Company’s global sales footprint and provide incremental growth for Amedica’s unique biomaterial will be significantly expanded, that scientific results may result in innovative solutions, increased market opportunities, growth, future products, market acceptance of its products, sales and financial results and similar statements are subject to risks and uncertainties such as whether the Chinese FDA will clear the products for use in China, the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica’s products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts:
Mike Houston
VP, Commercialization
801-839-3534
IR@amedica.com

Robert Haag
Managing Director
IRTH Communications
866-976-4784
amda@irthcommunications.com

Monday, April 18th, 2016 Uncategorized Comments Off on (AMDA) Signs Exclusive Chinese Silicon Nitride Distribution Agreement

(HRTX) Provides Update on FDA Review of SUSTOL® NDA

Heron Therapeutics, Inc. (NASDAQ: HRTX), announced today that the U.S. Food and Drug Administration (FDA) has provided the Company with an update on its review of the New Drug Application (NDA) for SUSTOL® (granisetron) Injection, extended release. The FDA has indicated that there are no substantive deficiencies in the NDA and has begun labeling discussions with the Company.

SUSTOL is a long-acting formulation of the FDA-approved 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist granisetron being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). SUSTOL is formulated utilizing Heron’s proprietary Biochronomer® drug delivery technology, and has been shown to maintain therapeutic drug levels of granisetron for at least five days with a single subcutaneous injection.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives of patients by developing best-in-class medicine that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron’s goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use. For more information, visit www.herontx.com.

Forward-Looking Statements

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those associated with: whether the U.S. Food and Drug Administration (FDA) completes its review within any anticipated time period, whether the FDA approves the SUSTOL NDA as submitted or supports as broad of a labeled indication for SUSTOL as requested, and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Heron Therapeutics, Inc.
Investor Relations Contact:
Jennifer Capuzelo, 858-703-6063
Associate Director, Investor Relations
jcapuzelo@herontx.com
or
Corporate Contact:
Barry D. Quart, 650-366-2626
Pharm D., Chief Executive Officer

Monday, April 18th, 2016 Uncategorized Comments Off on (HRTX) Provides Update on FDA Review of SUSTOL® NDA

(IPWR) Reports Semiconductor Fabricator Successfully Tested Its B-TRAN Technology

Third Party Testing of First B-TRAN Semiconductor Structures Validate Key Performance Characteristics

AUSTIN, TX–(Apr 18, 2016) – Ideal Power Inc. (NASDAQ: IPWR), a developer of innovative power conversion technologies, reported its semiconductor fabricator successfully tested Bi-Directional Bi-Polar Junction TRANsistor (B-TRAN™) silicon dies and test results validate key characteristics of the semiconductor power switch. The test results can be found in the company’s updated B-TRAN White Paper. The results confirm central B-TRAN™ elements and operational modes are consistent with third party device simulations that predict significant performance and efficiency improvements over conventional power switches such as SCRs, IGBTs and MOSFETs.

Ideal Power currently has 12 issued and over 40 patents pending in the United States and abroad related to the B-TRAN™ device, which is a symmetric double-sided structure that presents unique opportunities for high current density operation at high efficiency. B-TRANs have potential uses in a wide range of power conversion and control applications, including very low loss AC power control and in power converters from Ideal Power and other power converter OEMs.

“This validation of key characteristics of the B-TRAN™ technology is a significant step forward in demonstrating B-TRAN’s ability to improve energy efficiency across a wide range of products and applications,” said Dr. Richard Blanchard, B-TRAN™ co-inventor and holder of over 200 patents primarily related to power semiconductors including the widely used trench MOSFET. “The device has tremendous implications for the power industry.”

“These exciting results of the first tested B-TRAN™ structures validate key characteristics of the device and confirm our belief that B-TRANs can be a disruptive new force in many power conversion applications,” said Bill Alexander, CTO of Ideal Power and co-inventor of the B-TRAN™. “The predicted extremely low forward voltage drop and fast, low loss switching of the B-TRAN™ are each approximately ten times better than conventional switches. B-TRAN’s high current density and native bi-directional capability can lead to very high efficiency power control and conversion at very low cost points. We expect these anticipated efficiency improvements to translate to a substantial cost-performance advantage over current generation power semiconductor devices, which opens a multi-billion dollar market opportunity for the B-TRAN™ and is generating licensing inquiries from power semiconductor companies.”

Ideal Power plans to introduce the B-TRAN™ into the rapidly growing power semiconductor market, estimated to be $17 billion in 2015 according to research firm IHS Technology. The next major milestone for commercializing the B-TRAN™ will be testing a fully-packaged device.

Ideal Power believes its new B-TRAN™ technology can potentially address up to 50% of the power semiconductor market as a replacement for older, less efficient power switch technologies such as IGBTs and MOSFETs, as well as the newer gallium nitride (GaN) and silicon carbide (SiC) devices. Potential addressable markets for B-TRAN-based products include very low loss solid-state DC and AC contactors, electric vehicle drivetrains, variable frequency drives, solar photovoltaic inverters, bi-directional energy storage and microgrid power conversion systems, matrix converters and other power conversion products.

Based on third party simulations and testing to date, the Company expects the B-TRAN to deliver 10 to 200 times the cost-performance of current power semiconductor switches, depending on the switch type and configuration, with cost-performance being defined as the combination of device cost and on-state resistance. For a given cost, the B-TRAN™ is expected to have 10 to 200 times lower on-state resistance, while simultaneously having up to 10 times faster switching than other silicon-based switches.

About Ideal Power Inc.
Ideal Power Inc. (NASDAQ: IPWR) has developed a novel, patented power conversion technology called Power Packet Switching Architecture™ (PPSA). PPSA improves the size, cost, efficiency, flexibility and reliability of electronic power converters. PPSA can scale across several large and growing markets, including commercial grid storage, combined solar and storage, microgrids, and electrified vehicle charging. Ideal Power also has a capital-efficient business model that can enable it to address these markets simultaneously. Ideal Power has won multiple grants for its PPSA technology, including a $2.5 million grant from the Department of Energy’s Advanced Research Projects Agency – Energy (ARPA-E) program, and market-leading customers are incorporating PPSA as a key component of their systems. For more information, visit www.IdealPower.com.

Safe Harbor Statement
All statements in this release that are not based on historical fact are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Specific forward-looking statements include our comments about expected performance of B-TRAN™ products, potential technical advantages compared to competing technologies, potential markets we could address with our B-TRAN™ technology, and the potential market impact of this technology in these markets. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, whether the patents for our technology provide adequate protection and whether we can be successful in maintaining, enforcing and defending our patents, whether a demand for energy storage products will grow, whether demand for our products, which we believe are disruptive, will develop and whether we can compete successfully with other manufacturers and suppliers of energy conversion products, both now and in the future, as new products are developed and marketed. The B-TRAN™ is a new and novel technology. We may encounter difficulties manufacturing the B-TRAN™ (or having the B-TRAN™ manufactured) in commercial quantities with acceptable margins or at all, and commercially manufactured B-TRAN™ devices may not achieve the technical performance improvements we expect based on preliminary tests conducted to date. There are risks that the device might not achieve market acceptance in these markets. In addition, competitors may offer products based upon competing technologies that outperform the B-TRAN™. The costs of manufacturing, marketing and selling the B-TRAN™ may exceed our expectations so that we may not realize acceptable, or any, profit margins related to B-TRAN™ sales or license revenue. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

Ideal Power Media Contact:
Mercom Communications
www.mercomcapital.com
Wendy Prabhu
Email Contact
1.512.215.4452

Ideal Power Inc. Investor Relations Contact:
MZ North America
www.mzgroup.us
Matt Hayden
Email Contact
1.949.259.4986

Monday, April 18th, 2016 Uncategorized Comments Off on (IPWR) Reports Semiconductor Fabricator Successfully Tested Its B-TRAN Technology

(RXII) to Present at the Association for Research in Vision and Ophthalmology 2016

MARLBOROUGH, Mass., April 18, 2016  — RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present at the Association for Research in Vision and Ophthalmology (ARVO) 2016 annual meeting.  This meeting is the largest gathering of eye and vision researchers in the world drawing 11,000 attendees exploring cutting-edge science. This year’s conference will be held May 1-5, 2016 at the Washington State Convention Center in Seattle, Washington.

On Sunday, May 1, 2016, new data from ongoing research utilizing the Company’s proprietary RNAi platform in the area of therapeutic topical delivery to the eye, will be presented in the 3:15 – 5:00 p.m. PDT poster session: Corneal Wound Repair and Healing. These data may be viewed on Poster 1280 – D0228 entitled, “sd-rxRNA®: Self-Delivering RNAi Compounds Show Potential for Corneal Indications Following Topical Application.”

The poster will be available under the “Investors – Presentations & Posters” section of the Company’s website, www.rxipharma.com approximately 1 hour following the presentation.

About RXi’s Proprietary Self-delivering RNAi (sd-rxRNA®) Platform

Building on the pioneering work of Dr. Craig Mello, Nobel Laureate and RXi’s Scientific Advisory Board Chairman, scientists at RXi developed novel sd-rxRNA compounds where drug-like properties are built into the RNAi compound itself. These proprietary compounds are novel RNAi compounds with enhanced properties for therapeutic use including:  efficient spontaneous cellular uptake, stability, reduced potential for immune stimulation, and potent, long-lasting intracellular activity.  All cell types tested (primary, neuronal and non-adherent) internalize sd-rxRNA compounds uniformly and efficiently, resulting in potent and long lasting silencing.  Efficient cellular uptake is observed both in vitro and in vivo, as well as in tissues including skin, retina, lung, spinal cord and liver.

RXI-109, an sd-rxRNA compound designed to silence connective tissue growth factor (CTGF), which plays a key role in tissue regeneration and repair, is currently being evaluated in clinical trials.  A Phase 1/2 clinical study, RXI-109-1501, is underway to evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases. In addition, a Phase 2 clinical trial, RXI-109-1402, is currently evaluating RXI-109 as a treatment to reduce the recurrence of hypertrophic scars following scar revision surgery.  Over 100 subjects have been treated with RXI-109 by intradermal injection in all trials to date. Multiple intradermal injections were well tolerated at all dose levels.  RXI-109 was shown to cause a dose-dependent silencing of CTGF messenger RNA and protein levels in the treated areas of the skin compared to placebo and preliminary results from Phase 2a studies indicate a clinical effect on scar appearance.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs.  Building on the pioneering work of RXi’s Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma.  RXi’s robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company’s website, www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively “our product candidates”); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi’s product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors.”  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact

RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com

Monday, April 18th, 2016 Uncategorized Comments Off on (RXII) to Present at the Association for Research in Vision and Ophthalmology 2016

(CNCK) Engages Bonwick Capital Partners as Financial and Corporate Advisor

LOS ANGELES, CA and NEW YORK, NY–(Apr 18, 2016) – Content Checked Holdings, Inc. (OTCQB: CNCK) (the “Company”), a creator of mobile applications for people with dietary restrictions, today announced that the Company has engaged Bonwick Capital Partners LLC (“Bonwick”) as its financial and corporate advisor. Bonwick will assist the Company with its financial, corporate, and mergers and acquisitions strategy, as well as with the Company’s planned application submission for uplisting to NASDAQ later this fiscal year. Bonwick is a FINRA registered broker/dealer and SIPC member firm, providing top tier service to institutional clients across sales and trading, investment banking and corporate advisory.

In order to qualify for and maintain its listing, the Company will be required, among other things, to adhere to the corporate governance standards set forth by NASDAQ, including audit committee, independent directors, and management and officer compensation requirements.

Kris Finstad, the Company’s CEO and President, stated, “We are excited to work with Bonwick Capital in helping us execute our growth and financial strategy and with what has always been an important part of our corporate development plan: an uplisting to NASDAQ.” Mr. Finstad continued, “Bonwick Capital has assembled a specialized team of experienced financial and industry professionals who will play an essential role in our overall strategy of increasing shareholder value. Our planned uplisting to NASDAQ will allow us to tap into much broader capital market resources and further solidify our short- and long-term goals of successfully executing our business strategy.”

For more information on the Company, or to download its apps, please visit: www.contentchecked.com.

About Bonwick Capital Partners

Bonwick Capital Partners, LLC is a full-service broker dealer dedicated to providing top tier service to institutional clients across sales and trading, investment banking and corporate advisory business lines. Bonwick’s clients rely upon the firm’s deep industry knowledge to assist them through the investment process, sourcing deals, conducting due diligence, capital raises and business solutions. Bonwick has a diverse global client base, which spans five continents, and these relationships allow the firm to address a wide range of client needs across different time zones and cultures. Bonwick is headquartered in New York City with offices in Chicago and Los Angeles. For more information, go to www.bonwickcapital.com

About Content Checked Holdings, Inc.

Content Checked Holdings, Inc. (www.contentchecked.com) has created a revolutionary marketplace for people with dietary restrictions and the organizations who cater to them by creating and introducing the ContentChecked, MigraineChecked and SugarChecked smartphone applications. ContentChecked and MigraineChecked are the first applications with comprehensive and accurate content information, and in-depth allergen and migraine definitions for over 70% of conventional U.S. food products.

Each app gives consumers the ability to scan a product’s bar code and determine if it is safe for consumption based on their allergy settings. The apps will recommend a suitable alternative if a product does contain one or more of a user’s allergens. This enables the applications to meet the needs of millions of people in the U.S. In the U.S. alone, there are more than 15 million people who suffer from food allergies and 38 million people who suffer from migraines and chronic headaches. The food allergy and intolerances market has been valued at approximately US$13 billion in 2015. As a result, the Company has created a pivotal way for food manufacturers and producers to showcase their products to consumers who are actively seeking them at the point of purchase.

The Company has created a robust database of allergens, migraine triggers and food ingredients that directly correlate with food allergies, intolerances, migraines and chronic headaches. There are currently hundreds of thousands of products in its database, updated regularly. All applications serve as easy shopping tools for consumers to decipher often misleading food labels and receive recommendations for healthier alternative products as they shop in real time. The Company’s mission is to offer fast, reliable and efficient mobile apps that help consumers make more informed purchasing decisions and live healthier lives in accordance to their dietary preferences.

For more information on the Company, please visit its social media channels via Facebook (www.facebook.com/contentchecked), (www.facebook.com/migrainechecked) and (www.facebook.com/sugarchecked); Instagram (www.instagram.com/contentchecked), (www.instagram.com/migrainechecked) and (www.instagram.com/sugarchecked); or YouTube (www.youtube.com/channel/UCMihoaZILlRZ2C3hmx5vXhQ).

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2015, the Company’s Quarterly Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Contacts:
Investor Relations
Christine J. Petraglia
Managing Director, Investor Relations
PCG Advisory Group
535 5th Avenue, 24th Floor
New York, NY 10017
646-731-9817
www.pcgadvisory.com

Content Checked Holdings, Inc.
Victoria Nunez
Director of Business Development
8730 Sunset Blvd., Suite 240
West Hollywood, CA 90069
424-205-1777
www.contentchecked.com

Monday, April 18th, 2016 Uncategorized Comments Off on (CNCK) Engages Bonwick Capital Partners as Financial and Corporate Advisor

(EBIX) Signs Pioneering Contract to Deploy Single Exchange Platform

ATLANTA, GA–(Apr 15, 2016) – Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial and healthcare industries, today announced that it has signed a contract with Placing Platform Limited (PPL), to deploy a single insurance exchange across the entire London insurance marketplace, to facilitate electronic placement of insurance, while capturing and processing risks electronically. The PPL Board signed the contract on behalf of the International Underwriting Association (IUA), the London & International Insurance Brokers’ Association (LIIBA) and the Lloyd’s Market Association (LMA).

In 2013, the London Market Group’s (LMG) Future Process review concluded, amongst other things, that the market needed to improve its accessibility by delivering a central placing platform. This platform would support a flexible negotiation process, facilitate access to the market and offer faster placement for the benefit of the client. The platform would support both traditional face-to-face negotiations and purely electronic placements or a combination of both. The IUA, LIIBA and LMA agreed that such a central placing platform would be best delivered via a market utility. As a result, the PPL was formed with full support from both broker and insurer firms, to coalesce around a single electronic “platform.” PPL was set up as a genuine team effort with all sectors of the market being brought together in a fully representative organization.

A total of 26 subject matter expert practitioners, representing both carriers and brokers, were involved in the selection process, drawing up a detailed description of requirements. Independent consultants were hired to ensure the selection process was objective, transparent and fair. After a thorough evaluation process, PPL selected Ebix’s team and technology for the provision, governance and management of the platform.

Over the last few years, Ebix has worked closely with PPL to enhance the platform to meet the London modernization goals, while completing extensive platform testing. Ebix also disclosed that its contract with PPL is primarily a subscription contract that is expected to generate upwards of $75 million over the next 5 years ($15 million per year) from the electronic placement exchange service, with more than 85% of that number coming from annual subscription fees payable to Ebix. Ebix will bill PPL for its services, which in turn will be funded by all the market constituents, funding commitments for which have already been secured by PPL.

David Ledger, Chairman of PPL commented: “We are delighted that the contract has been signed. Ebix has been really supportive through the process and worked closely with the PPL team to make sure the project stayed on track. We are excited about working with them to take the launch forward, and are confident that the combination of their technology and the market’s insurance expertise will make for a world class solution which will make London an easier place to do business.”

Robin Raina, President & CEO of Ebix said, “It is the first time in the world that a single Exchange platform is being deployed to facilitate electronic placement of insurance across a market comprised of all the constituents. That it is being done by the largest insurance marketplace in the world — London — makes this a particularly significant event in the global insurance market. We are honored and excited to be powering the technology behind this Exchange endeavor and are committed to doing everything within our means to make this world-leading, ground-breaking effort a huge success. I congratulate PPL, LMG and Lloyds for taking the initiative to modernize the London market as a part of LMG’s Target Operating Model (TOM) and assure them of our complete support.”

Some Benefits of the Exchange –
There are considerable advantages derived from the Exchange, not the least of which is the avoidance of considerable costs incurred by carriers integrating with multiple placing systems rather than a single market utility. It is estimated that carriers could avoid over $90 million in such set-up costs and $18 million annually, by supporting one system. Economies of scale and the potential to reduce redundant data-entry and other functions should contribute further financial advantages.

The PPL is also likely to further enhance the London market’s leadership and global reputation. With this exchange, London will be the first and only commercial insurance market globally to implement electronic placing. It will be able to provide real time status updates to clients on the progress of quotes 24 hours a day. Clean, standard, structured contracts will replace scanned versions with manual stamps. Signed line confirmations to carriers could be accelerated by up to 30 days.

Such improvements will make the London market a more efficient place to do business. There is a consensus that London has to continue to modernize to attract more global insurance business and this exchange is designed to lower placement costs and make the market more accessible to international clients.

About Ebix, Inc.
A leading international supplier of On-Demand software and E-commerce services to the insurance, financial and healthcare industries, Ebix, Inc., (NASDAQ: EBIX) provides end-to-end solutions ranging from infrastructure exchanges, carrier systems, agency systems and risk compliance solutions to custom software development for all entities involved in the insurance industry.

With 40+ offices across Brazil, Singapore, Australia, the US, UK, New Zealand, India and Canada, Ebix powers multiple exchanges across the world in the field of life, annuity, health and property & casualty insurance while conducting in excess of $100 billion in insurance premiums on its platforms. Through its various SaaS-based software platforms, Ebix employs hundreds of insurance and technology professionals to provide products, support and consultancy to thousands of customers on six continents. For more information, visit the Company’s website at www.ebix.com

SAFE HARBOR REGARDING FORWARD-LOOKING STATEMENTS
As used herein, the terms “Ebix,” “the Company,” “we,” “our” and “us” refer to Ebix, Inc., a Delaware corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only Ebix, Inc.

The information contained in this Press Release contains forward-looking statements and information within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of the Company’s products by the market, and management’s plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “seeks,” “plan,” “project,” “continue,” “predict,” “will,” “should,” and other words or expressions of similar meaning are intended by the Company to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference. These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.

Our actual results may differ materially from those expressed or implied in these forward-looking statements. Factors that may cause such a difference, include, but are not limited to those discussed in our Annual Report on Form 10-K and subsequent reports filed with the SEC, as well as: the risk of an unfavorable outcome of the pending governmental investigations or shareholder class action lawsuits, reputational harm caused by such investigations and lawsuits, the willingness of independent insurance agencies to outsource their computer and other processing needs to third parties; pricing and other competitive pressures and the Company’s ability to gain or maintain share of sales as a result of actions by competitors and others; changes in estimates in critical accounting judgments; changes in or failure to comply with laws and regulations, including accounting standards, taxation requirements (including tax rate changes, new tax laws and revised tax interpretations) in domestic or foreign jurisdictions; exchange rate fluctuations and other risks associated with investments and operations in foreign countries (particularly in Australia and India wherein we have significant operations); equity markets, including market disruptions and significant interest rate fluctuations, which may impede our access to, or increase the cost of, external financing; and international conflict, including terrorist acts.

Except as expressly required by the federal securities laws, the Company undertakes no obligation to update any such factors, or to publicly announce the results of, or changes to any of the forward-looking statements contained herein to reflect future events, developments, changed circumstances, or for any other reason.

Readers should carefully review the disclosures and the risk factors described in the documents we file from time to time with the SEC, including future reports on Forms 10-Q and 8-K, and any amendments thereto.

You may obtain our SEC filings at our website, www.ebix.com under the “Investor Information” section, or over the Internet at the SEC’s web site, www.sec.gov.

CONTACT:
Darren Joseph
678 -281-2027
Email Contact

David Collins or Chris Eddy
Catalyst Global
212-924-9800
Email Contact

Friday, April 15th, 2016 Uncategorized Comments Off on (EBIX) Signs Pioneering Contract to Deploy Single Exchange Platform

(NAVB) and Macrophage Therapeutics to Provide Business Update

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announces a conference call on Monday, April 18, 2016 at 4:30 p.m. ET to update the market on recent events. The recent changes to the board provide Navidea with an opportunity to refocus its efforts and to develop a strategic plan that takes maximum advantage of its Manocept™ macrophage targeting technology for immunodiagnostic and immunotherapeutic applications.

Lymphoseek® (technetium Tc 99m tilmanocept) injection represents the first of many potential products that can be developed with this technology. In addition, Lymphoseek, which is currently approved in the U.S. and Europe to guide sentinel lymph node biopsy in breast cancer, melanoma, and oral cavity cancers and in the U.S. for use in solid tumors where lymphatic mapping is a component of surgical management, is being explored for additional immunodiagnostic uses including rheumatoid arthritis as the initial target and ultimately for other autoimmune and inflammatory conditions including cardiovascular disease, infectious diseases and a number of other potential indications. On the immunotherapeutic side there has been significant progress and with the changes at the board level, we are committed to providing the necessary support to enable this effort to achieve its potential.

To achieve our ambitious goals our immediate objective is to right size our expenses to our current revenues so that we attain positive operational cash flow, based on our current revenue stream. Given our projected revenue growth and profitability and a renegotiated distribution agreement following its expiration in less than 2 years, we believe that our ability to refinance our existing senior debt with improved terms is very likely.

In addition we will present an update on the very significant progress that has occurred at Macrophage Therapeutics, the immunotherapeutic-focused subsidiary of Navidea. Over the past six months we have successfully developed new chemical synthetic processes for the synthesis of the first two therapeutic products. These compounds have appropriate purity and have demonstrated high affinity binding to the CD206 (mannose receptor) target. Two different contract manufacturing organizations have successfully produced the materials and there are plans for GMP scale-up as the programs move forward. We have also completed a number of animal studies with our intended anti-inflammatory compound and are in the process of completing dosing in a number of additional animal studies with either our anti-inflammatory compound or our compound designed to destroy via apoptosis disease causing macrophages. We are also in the process of initiating several animal in vivo tumor model studies to investigate the ability to deplete Tumor Associated Macrophages (TAMs) and initiate cancer cell death. As we stated when we created Macrophage Therapeutics, we will be pursuing a partnership model, as we look to explore the many potential uses for this technology in parallel. We have successfully introduced the technology to multiple large pharmaceutical and biotechnology companies and it is our intent to pursue development deals based on their review of the data we are currently generating. We have recently initiated the first collaboration with a large pharmaceutical company that is testing one of our compounds in various anti-inflammatory studies. We will review the current state of affairs at Macrophage Therapeutics on Monday’s call.

Finally we are eager to open the call to Navidea investors and potential investors. We will devote a substantial portion of the call to Q&A as we want to make certain we address the subjects that are important to investors. We plan to discuss the progress of this promising technology during regularly scheduled Macrophage Therapeutics update calls as we appreciate the value of improving communication with investors and prospective investors.

Conference Call Details

Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event.

Event: Navidea and Macrophage Therapeutics Business Update Call
Date/Time: Monday, April 18, 2016 at 4:30 p.m. ET
Webcast Link: http://edge.media-server.com/m/p/e2rzwvkp
Dial-in Number – US: (855) 897-5884
Dial in Number – Int’l: (720) 634-2940
Participant Passcode: 93499436
Replay A webcast replay will be available on the Investor Relations section of our
website at http://ir.navidea.com for 30 days.

About Lymphoseek

Lymphoseek® (technetium Tc 99m tilmanocept) injection is the first and only FDA-approved receptor-targeted lymphatic mapping agent. It is a novel, receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. Lymphoseek is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. Lymphoseek is approved by the U.S. Food and Drug Administration (FDA) for use in solid tumor cancers where lymphatic mapping is a component of surgical management and for guiding sentinel lymph node biopsy in patients with clinically node negative breast cancer, melanoma or squamous cell carcinoma of the oral cavity. Lymphoseek has also received European approval in imaging and intraoperative detection of sentinel lymph nodes in patients with melanoma, breast cancer or localized squamous cell carcinoma of the oral cavity.

Accurate diagnostic evaluation of cancer is critical, as results guide therapy decisions and determine patient prognosis and risk of recurrence. Overall in the U.S., solid tumor cancers may represent up to 1.2 million cases per year. The sentinel node label in the U.S. and Europe may address approximately 600,000 new cases of breast cancer, 160,000 new cases of melanoma and 100,000 new cases of head and neck/oral cancer diagnosed annually.

Lymphoseek Indication and Important Safety Information

Lymphoseek is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

• Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management.

• Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Important Safety Information

In clinical trials with Lymphoseek, no serious hypersensitivity reactions were reported, however Lymphoseek may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Prior to the administration of Lymphoseek, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of Lymphoseek administration, and patients observed for signs or symptoms of hypersensitivity following injection.

Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers. In clinical trials, no patients experienced serious adverse reactions and the most common adverse reactions were injection site irritation and/or pain (<1%).

FULL LYMPHOSEEK PRESCRIBING INFORMATION CAN BE FOUND AT:

WWW.LYMPHOSEEK.COM

About Manocept CD206 Immunotargeting Platform for Therapeutics Development

Manocept™ CD206 Immunotargeting Platform is a proprietary mannose-containing, receptor-directed technology platform designed to engineer novel, synthetic receptor targeted imaging agents and therapeutics for cancer and other diseases. Manocept’s unique structural and molecular properties enable the design of novel immuno-constructs that selectively target and bind to CD206 (mannose receptor) and other C-type Lectins found on activated, disease-associated macrophages and tumor associated macrophages (TAMs). The Manocept CD206 Immunotargeting Platform provides a novel and valuable approach to the design of drug molecules targeting CD206 disease-associated macrophages for therapeutic purposes.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. The development activities of the Manocept immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

About Macrophage Therapeutics

Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NAVB), is developing therapeutics using the patented Manocept immunotherapy platform licensed from Navidea to target over-active macrophages implicated in cancer, cardiovascular, central nervous system, autoimmune, antiviral, and skin diseases. Manocept specifically targets CD206, or the mannose receptor prevalent on over-active macrophages. The technology enables highly specific targeted delivery of active (either existing or yet to be developed) agents that can modulate the activity of over-active macrophages that have been implicated in many diseases. Targeted delivery should significantly enhance a given compound’s efficacy and safety.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

 

For Navidea Biopharmaceuticals:
Investors & Media
Sharon Correia, 978-655-2686
Senior Director, Corporate Communications

Friday, April 15th, 2016 Uncategorized Comments Off on (NAVB) and Macrophage Therapeutics to Provide Business Update

(PTCT) NICE Recommends Translarna™

-Positive Recommendation Enables Reimbursed Patient Access to First Approved Therapy to Treat Underlying Cause of Devastating Rare Disease-

SOUTH PLAINFIELD, N.J., April 15, 2016  — PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna ∇ (ataluren) for ambulatory patients aged five years and older with nonsense mutation Duchenne muscular dystrophy (nmDMD) in connection with a Managed Access Agreement (MAA) with NHS England.  The provision of patient access is subject to the finalization of the NICE draft guidance, which the agency expects in May of 2016.

“This is an important day for the Duchenne community, which has been working hard to make this ground-breaking drug available to boys with nonsense mutation Duchenne muscular dystrophy,” said Paul Lenihan, Chief Executive of Action Duchenne. “We are delighted by this positive recommendation and NICE’s recognition that Translarna is an important new medicine for patients. This decision is a hugely encouraging sign that both NICE and NHS England have listened to the patient community, bringing hope to each and every parent and patient fighting DMD.”

Primarily affecting males, Duchenne muscular dystrophy (DMD) is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of skeletal, diaphragm, and heart muscles. Patients with DMD lose the ability to walk from as early as 10 years of age and experience life-threatening lung and heart complications in their late teens and early twenties.

“We are extremely pleased by the NICE recommendation, which recognizes Translarna as an innovative medicine with the potential to change the course of this devastating disease,” said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc.  “This is a crucial step for the boys and young men in England with nonsense mutation DMD. We are grateful to the patients, families, advocacy groups and physicians who have supported PTC Therapeutics through this important access process and look forward to working with NHS England to conclude the managed access agreement.”

PTC and NHS England are in the process of finalizing an MAA outlining financial and clinical details surrounding the use of Translarna, including a confidential financial arrangement. The MAA is expected to allow PTC to collect further data on the efficacy of Translarna for the treatment of nmDMD over a five-year period with NICE guidance to be reviewed again at the end of that period.

Translarna was approved by the European Commission in August 2014 to treat nmDMD and is currently available to patients in 23 countries through either expanded access programs or commercial sales.

About Translarna™ (ataluren)
Translarna, discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Translarna is an investigational new drug in the United States. The development of Translarna has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA’s Office of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

Further information about Translarna, including the European Public Assessment Report, Summary of Product Characteristics and Patient Information Leaflet, is available on the European Medicines Association website.

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system or to PTC at medinfo@ptcbio.com.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. PTC’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com.

For More Information:

Investors:
Jane Baj
+1 (908) 912-9176
jbaj@ptcbio.com

Media:
Justine O’Malley
+1 (908) 912-9551
jomalley@ptcbio.com

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact, contained in this release are forward-looking statements, including statements about our expectations regarding the potential timing and outcome of final guidance from NICE with respect to Translarna for the treatment of nmDMD; the ability of NHS England and PTC Therapeutics to finalize a MAA in a timely manner, whether on terms acceptable to PTC, or at all; the potential timing, if ever, of the provision of patient access to Translarna for nmDMD in England; the timing and scope of PTC’s commercial and early access program launches; the rate and degree of market acceptance of Translarna; the clinical utility and potential advantages of Translarna; PTC’s estimates regarding the potential market opportunity for Translarna, including the size of eligible patient populations and PTC’s ability to identify such patients; future expectations, plans and prospects for PTC; PTC’s strategy, future operations, future financial position, future revenues or projected costs; and the objectives of management.  Other forward-looking statements may be identified by the words “plan,” “guidance,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: whether final guidance from NICE recommends Translarna for the treatment of nmDMD; actual reimbursement decisions by NHS England and the acceptability of final terms of the MAA; PTC’s ability to maintain the marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area, or EEA, which is subject to ongoing conditions and is also subject to annual review and renewal by the EMA following its reassessment of the risk benefit balance of the authorization; PTC’s ability to commercialize and commercially manufacture Translarna in general and specifically as a treatment for nmDMD, including its ability to successfully negotiate favorable pricing and reimbursement processes on a timely basis in the countries in which it may obtain regulatory approval; the timing and outcome of future interactions PTC has with the FDA with respect to Translarna for the treatment of nmDMD, including whether PTC is required to perform additional clinical and non-clinical trials at significant cost and whether such trials, if successful, may enable FDA review of a NDA submission; whether the FDA, the EMA or other regulators agree with PTC’s interpretation of the results of ACT DMD and other data with respect to the safety and efficacy of Translarna for the treatment of nmDMD or PTC’s other clinical trials; the outcome of pricing and reimbursement negotiations in those territories in which PTC is authorized to sell Translarna; whether patients and healthcare professionals may be able to access Translarna through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome, including whether Translarna may be accessed through a reimbursed importation pathway provided under German law and whether such pathway will minimize any access issues for German patients while maintaining a sustainable price; expectations for regulatory approvals, including PTC’s ability to make or advance regulatory submissions in a timely manner (or at all), the period during which the outcome of regulatory reviews will become available, adverse decisions by regulatory authorities, other delay or deceleration of the regulatory process, and PTC’s ability to meet existing or future regulatory standards with respect to Translarna; the scope of regulatory approvals or authorizations for Translarna (if any), including labeling and other matters that could affect the availability or commercial potential of Translarna; PTC’s ability to fulfill any additional obligations, including with respect to further trials or studies relating to cost-effectiveness, obtaining licenses or satisfying requirements for labor and business practices, in the territories in which it may obtain regulatory approval; the initiation, conduct and availability of data from clinical trials and studies; PTC’s scientific approach and general development progress; the eligible patient base and commercial potential of Translarna and PTC’s other product candidates; and the factors discussed in the “Risk Factors” section of PTC’s most recent Annual Report on Form 10-K as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that Translarna will receive full regulatory approval in any territory or maintain its current marketing authorization in the EEA, or prove to be commercially successful in general, or specifically with respect to the treatment of nmDMD.

The forward-looking statements contained herein represent PTC’s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this release except as required by law.

Friday, April 15th, 2016 Uncategorized Comments Off on (PTCT) NICE Recommends Translarna™

(GBSN) Strong 1st Quarter Customer Growth Could Indicate Stronger Future Revenue Growth

NEW YORK, NY / April 15, 2016 / Great Basin Scientific, Inc. (NasdaqCM: GBSN) is a molecular diagnostic company that commercializes breakthrough chip-based technologies. The company’s vision is to make molecular testing so simple and cost-effective that every patient will be tested for ever serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease.

What could strong customer growth mean for the company’s stock price?

Get the company background and analyst comments on Great Basin Scientific, Inc. (NASDAQCM: GBSN) please follow this link. There is no cost obligation required to view analyst brief: http://broadstreetalerts.com/future-revenue-growth/.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Mike McCord. An outsourced research services provider represented by Mike McCord, provided Broad Street Alerts this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Broad Street Alerts is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Mike McCord. The subject Company has not compensated Broad Street Alerts or Mike McCord for the creation or dissemination of this report. Broad Street Alerts is the party responsible for issuing the press release and for hosting the full analyst report on Broad Street Alerts website. Mike McCord is the author of research report. This information is submitted to increase awareness for the broad Street Alerts brand to our subscriber base and the investing public.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@BroadStreetAlerts.com. For any urgent concerns or inquiries, please contact us at admin@BroadStreetAlerts.com.

NOT FINANCIAL ADVICE

Broad Street Alerts makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Broad Street Alerts is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Broad Street Alerts has compensated Mike McCord, seventy dollars for the distribution rights to disseminate analyst report. No liability is accepted by Broad Street Alerts whatsoever for any direct, indirect or consequential loss arising from the use of this document. Broad Street Alerts expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Broad Street Alerts does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Friday, April 15th, 2016 Uncategorized Comments Off on (GBSN) Strong 1st Quarter Customer Growth Could Indicate Stronger Future Revenue Growth

(OGES) Reports 2015 Annual Results and Recent Highlights

Cash on Hand Tops $13 Million As the Company Completes Its $40 Million Manufacturing Facility and Begins Shipping Orders

MELBOURNE, FL / April 15, 2016 / Oakridge Global Energy Solutions, Inc. (OTCQB: OGES), a leading US-based technology manufacturer of lithium-ion batteries for military, civilian and medical applications, has today announced financial results for the year ended December 31, 2015 together with recent company highlights.

For the year ended December 31, 2015 the Company remained in pre-revenue phase while completing essential modifications to its new manufacturing facility into which the Company moved in October 2015. The Company booked a net income of $12 million attributed to a one-time other income transaction, compared to a net loss of $9 million in 2014. Total assets increased to $28 million compared to $6 million the year prior. The Company announced it has begun shipping orders in Q1 2016 following the opening of its state-of-the-art $40 million first-of-kind facility.

Full Year & Recent Highlights

– Completion of first-of-kind US-based rechargeable battery facility

– $13 million year-end cash on hand

– Existing pipeline orders of $24 million

– 30% increase in battery life cycle through its proprietary chemistry and technology

– First reported Company revenues in Q1 2016 for its Pro Series battery

– Pays off all outstanding debt ($2 million)

– Strategic Business Alliance Agreement with Sojitz Machinery Corporation of Tokyo, Japan to supply and finance raw materials and expansion of manufacturing equipment

– $30 million in State and local tax credits

– Significant additional new capital equipment on order

Steve Barber, CEO, commented, “In 2015 we significantly advanced our strategy to become a leading global rechargeable battery manufacturer focused on military, civilian and medical applications. We have successfully completed our 2-year restructuring plan and are now beginning to ship our proprietary technology rechargeable batteries to a long list of waiting customers. The April 1, 2016 U.N Agency ban on transporting lithium batteries on passenger planes further positions us to become a major manufacturing player in the rechargeable battery market in the USA.”

“As we transformed our business in 2015 I am particularly pleased with balance sheet liquidity–paying down all of our $2 million debt on one side and a pending stream of customer orders on the other. Our investment in future growth drivers also continues unabated. A recent strategic alliance with Sojitz–which is a world leader in factory automation plants, builder of world-class automated manufacturing facilities for leading global companies, as well as a specialist in the provision of raw materials and manufacturing needs to the lithium battery industry–further affirms that we are on the right track. Oakridge has entered 2016 with a robust pipeline of commercialization opportunities and orders. With our new facility and ongoing manufacturing plant expansion we are positioned for global leadership in the rechargeable battery space. Our top priority is to ship open orders to customers as efficiently and quickly as possible, with second shifts now in place to expedite the manufacturing process. We expect to deliver strong results in 2016, generating significant top-line growth while continuing to invest in our capacity.”

Barber concluded, “With an endless ocean of rechargeable battery applications plus an expansion of our existing product lines for golf carts motorcycle starter batteries, power sports and battery-powered freight trucks–which have a significantly reduced per-mile cost, plus the added benefit of greater leverage in our cost structure–our revenue and earnings power will notably increase. Our confidence is underscored by a growing backlog, which has expanded to $24 million in the last few months, reaching the highest levels since inception. Today, Oakridge is positioned for success with a lean cost structure and growing revenues–in addition, of course, to products and services that continue to make a meaningful impact on lives of customers.”

About Oakridge Global Energy Solutions, Inc.

Oakridge Global Energy Solutions Inc. leads in the innovation, development, manufacturing and marketing of disruptive energy storage technology for military, civilian and medical uses. The company’s research & development has led to some of the world’s longest-lasting rechargeable power sources currently available, with a battery life up to 3 times greater and a 30 percent longer cycle between charges than its foreign-manufactured counterparts. Located in Palm Bay, Florida, the Company operates the only lithium-ion battery manufacturing facility in the United States. For more information visit: www.oakridgeglobalenergy.com.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

Contact:

Oakridge Global Energy Solutions, Inc.
Name: Suzanna Barber
Phone: (321) 610-7959
Email: IR@oakg.net

Friday, April 15th, 2016 Uncategorized Comments Off on (OGES) Reports 2015 Annual Results and Recent Highlights

(TRIL) to Provide Update on CD47 Program at the 2016 AACR

TORONTO, ONTARIO–(April 14, 2016) – Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program, targeting the CD47 protein, at the 107th Annual Meeting of the American Association for Cancer Research. The meeting will be held April 16-20, 2016 in New Orleans, LA. Details of the poster presentation, entitled “SIRPaFc, a CD47-Blocking Cancer Immunotherapeutic, Triggers Phagocytosis of Lymphoma Cells by Both Classically (M1) and Alternatively (M2) Activated Macrophages“, are listed below:

Date: Monday April 18, 2016
Time: 1:00 pm – 5:00 pm (CT)
Session Category: Immunology
Session Title: Immune Checkpoints 1
Abstract #: 2345
Presenter: Dr. Natasja Nielsen Viller
Location: Section 26

The company will present data demonstrating that its SIRPaFc fusion protein, which targets the CD47 “do not eat” signal, promotes the phagocytosis of lymphoma cells by diverse types of macrophages. The studies also assess the impact of macrophage polarizing agents on drug activity and delineate the role of different Fc gamma receptors in promoting tumor cell killing by SIRPaFc.

“Macrophages are heterogeneous and certain types, notably M2s, are often implicated in tumor progression,” commented Trillium’s Chief Scientific Officer, Dr. Robert Uger. “Our data indicate that TTI-621, our CD47-blocking decoy receptor, enables all macrophage subsets tested, including M2s, to kill tumor cells. These results suggest that TTI-621 is able to convert otherwise pro-tumor macrophages into efficient anti-tumor effector cells. Rather than ablating M2 macrophages in the tumor microenvironment, these data support using TTI-621 to unleash their tumoricidal function.”

About Trillium Therapeutics:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The Company’s lead program, SIRPaFc, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin. It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc (TTI-621) is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the Company’s most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect Trillium’s current expectation regarding future results, events or developments, including our belief that TTI-621 is able to convert pro-tumor macrophages into efficient anti-tumor effector cells. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company’s ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
+1 416 595 0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com

Thursday, April 14th, 2016 Uncategorized Comments Off on (TRIL) to Provide Update on CD47 Program at the 2016 AACR

(ORPN) to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose

Final Results of 24-Week Open-Label Phase 2 Trial Will be Presented by Professor Zohar Argov, MD, Senior Medical Advisor to BioBlast Pharma

NEW HAVEN, Conn., April 14, 2016  — BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive final results from its HOPEMD Phase 2 six-month open-label clinical study in patients with oculopharyngeal muscular dystrophy (OPMD) at the 2016 American Academy of Neurology (AAN) Annual Meeting, being held in Vancouver, Canada April 15-21.  OPMD is a rare progressive muscle-wasting disease characterized by swallowing difficulties (dysphagia), leading to the risk of aspiration of food into the lungs, weight loss, and generalized progressive muscle weakness.

American Academy of Neurology 2016 Annual Meeting
April 15-21 in Vancouver, Canada

Title:           Intravenous Trehalose for Treatment of Dysphagia and Muscle Function in Oculopharyngeal
Muscular Dystrophy (OPMD): Final Results of 24 Week Open-Label Phase 2 Trial
Session:     Integrated Neuroscience Session – Advances in Acquired and Genetic Muscle Diseases
Date:          Sunday, April 17, 2016
Time:          5:00pm Pacific Time
Presenter:  Prof. Zohar Argov M.D.
Senior Medical Advisor to BioBlast Pharma

Session:      S28: Experimental Therapies in Neuromuscular Diseases
Date:           Tuesday, April 19, 2016
Time:           7:15am Pacific Time
Presenter:   Prof. Zohar Argov M.D.
Senior Medical Advisor to BioBlast Pharma

Twenty-four week results from the HOPEMD Phase 2 open-label study were announced by BioBlast on March 16th, 2016. Trehalose 90mg/mL IV solution was observed to be safe and well-tolerated with no drug-related serious adverse events.  Improvements versus baseline were observed in multiple secondary efficacy endpoints related to dysphagia and muscle strength and function.

About Trehalose 90mg/mL IV Solution
Trehalose 90mg/mL IV solution is a chemical chaperone that protects against pathological processes in cells.  It has been shown to reduce pathological aggregation of proteins within cells in several diseases associated with abnormal cellular-protein aggregation as well as acting as an autophagy enhancer.  Trehalose 90mg/mL IV solution has been documented as demonstrating significant promise in preclinical animal models of OPMD and other PolyA/PolyQ diseases.

In OPMD, trehalose 90mg/mL IV solution is being developed to prevent the aggregation of the pathological protein (PABPN1) in muscle cells, the hallmark of the disease, by stabilizing the protein, reducing the formation of protein aggregations, and promoting their clearance from cells through autophagy, thus preventing muscle cell death.

About Oculopharyngeal Muscular Dystrophy (OPMD)
OPMD is an inherited myopathy characterized by dysphagia (difficulty in swallowing), eyelid drooping (ptosis), the loss of muscle strength, and weakness in multiple muscles of the body.  Symptoms generally appear in mid-life and get worse over time.  As the dysphagia becomes more severe, patients become malnourished, lose significant weight, and may suffer from repeated incidents of aspiration pneumonia.  Aspiration pneumonia and severe emaciation may result in death.  The disease is caused by a genetic mutation responsible for the creation of a mutant protein (PABPN1) with an expanded polyalanine domain that aggregates within patient muscle cells.  There is currently no approved pharmacologic treatment for OPMD.

About BioBlast Pharma Ltd.
BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company has a portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on a deep understanding of disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.  BioBlast was founded in 2012 and is traded on the NASDAQ under the symbol “ORPN”. For more information, please visit the Company’s website, www.bioblast-pharma.com, the content of which is not incorporated herein by reference.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when it discusses, potential uses of its product candidates for various indications, building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases, or that BioBlast’s platforms potentially offer solutions for several diseases that share the same biological pathology. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or those historic results referred to in this press release would not be interpreted differently in light of additional research and clinical and preclinical trial results. Because such statements deal with future events and are based on BioBlast Pharma Ltd.’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of BioBlast Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading “Risk Factors” in BioBlast Pharma’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 29, 2016, and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

 

INVESTOR CONTACT: 
Matthew P. Duffy
Managing Director
LifeSci Advisors, LLC
Telephone:  212-915-0685
Thursday, April 14th, 2016 Uncategorized Comments Off on (ORPN) to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose

(GBSN) Announces Q1 Revenues and Customer Acquisition Results

Company sees 59.4% growth in revenue, and 119.8% customer growth year-over-year; will provide customer acquisition targets and 2016-2017 product roadmap on Business Update Call later today

Great Basin Scientific, Inc. (Nasdaq:GBSN), a molecular diagnostics company, today reported preliminary revenue results for the first quarter 2016. For the first quarter 2016, revenue was $731,422, an increase of 59.4% over the first quarter of 2015. The Company also reported that its customer base of revenue generating customers grew to 222 as of March 31, 2016, an increase of 119.8% over first quarter last year. The company will provide guidance for the 2016-2017 customer acquisition targets and menu expansion on a call later today.

“We are extremely pleased with the Company’s execution over the last 12 months, including our ability to significantly grow our customer base, develop and launch new tests, and the accelerating growth in our revenues,” said Ryan Ashton, Co-founder and Chief Executive Officer of Great Basin. “We’re committed to building on this momentum in 2016, by advancing the development of new molecular tests and panels that will differentiate our platform and increase potential revenue per customer. We remain dedicated to executing on the fundamentals that will serve both our target market and our stockholders, and look forward to sharing these plans during our Business Update call this afternoon.”

Great Basin invites all interested parties to join the call by dialing 877-407-0789. The call will also be broadcast live over the internet and can be accessed on the Investor Relations section of the Company’s website at www.gbscience.com.

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease.

Forward-Looking Statements

This press release includes forward-looking statement regarding events, trends and business prospects, which may affect our future operating results and financial position, including statements regarding the Company’s anticipated revenues and customer acquisitions, the Company accelerating its ability to develop and launch the tests and panels, that such tests and panels will differentiate the Company’s solution offering and other similar statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history or losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2015. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

 

Media:
ICR
Kate Ottavio Kent, 203-682-8276
Kate.Ottavio-Kent@icrinc.com
or
Investor Relations:
CorProminence
Scott Gordon, 516-222-2560
gbinfo@corprominence.com
or
ICR
David Clair, 646-277-1266
David.Clair@icrinc.com

Thursday, April 14th, 2016 Uncategorized Comments Off on (GBSN) Announces Q1 Revenues and Customer Acquisition Results

(DRWI) Successfully Completes First Five Harmony Enhanced MC Trials

DragonWave has successfully completed five customer trials of Enhanced MC, with five additional trials planned over the next three months

OTTAWA, CANADA–(April 14, 2016) – DragonWave Inc. (TSX:DWI)(NASDAQ:DRWI), a global supplier of packet microwave radio systems, today announced that they have successfully completed five customer trials of the newly launched Harmony Enhanced MC dual carrier product. DragonWave has also scheduled five additional trials of Harmony Enhanced MC to be conducted in the next three months.

“Operators are finding that Harmony Enhanced MC can be easily deployed today to expand backhaul capacity on their overburdened networks, while offering them the capacity and functionality to support next-generation network builds,” said Earl Lum, founder and president, EJL Wireless Research. “Harmony Enhanced MC provides a cost-effective solution today with added value capabilities to support backhaul demands for 5G.”

The completed trials successfully demonstrated the full range of Harmony Enhanced MC capabilities, resulting in positive feedback about the radio’s high capacity performance and industry-leading system gain. Discussions continue with the respective operators where Harmony Enhanced MC can be used for high capacity LTE, while readying the backhaul network for future 5G deployments. The trials were conducted both in lab and outdoor deployments, with first trials run in North America and further trials planned in Europe and The Middle East.

“The successful completion of these trials has demonstrated the industry-leading functionality of Harmony Enhanced MC,” said Greg Friesen, vice president, Product Management, DragonWave. “We are excited to see verification of the tested features that address the business case challenges for 4G backhaul networks, while also providing the network scalability to address future 5G deployments.”

Harmony Enhanced MC delivers the next level of capacity by introducing integrated dual carrier and fully integrated XPIC capabilities into a single Outdoor Unit (ODU). With its integrated switch, and the Industry’s first 10GE port on a wireless backhaul radio, Harmony Enhanced MC delivers a true all-outdoor, Ethernet solution with unmatched system gain and spectral efficiency. With integrated 112 MHz channel support, 4096QAM capability, Bandwidth Accelerator+ and MIMO, Harmony Enhanced MC delivers over 4 Gbps in a single radio, with scalability to deliver 8Gbps on a single antenna. The Harmony Enhanced MC also provides the highest systems gain in an all-outdoor microwave system, leveraging the latest RF ASIC technology to increase reach by more than 30% reducing tower costs.

About DragonWave

DragonWave® is a leading provider of high-capacity packet microwave solutions that drive next-generation IP networks. DragonWave’s carrier-grade point-to-point packet microwave systems transmit broadband voice, video and data, enabling service providers, government agencies, enterprises and other organizations to meet their increasing bandwidth requirements rapidly and affordably. The principal application of DragonWave’s portfolio is wireless network backhaul, including a range of products ideally suited to support the emergence of underlying small cell networks. Additional solutions include leased line replacement, last mile fiber extension and enterprise networks. DragonWave’s corporate headquarters is located in Ottawa, Ontario, with sales locations in Europe, Asia, the Middle East and North America. For more information, visit http://www.dragonwaveinc.com.

DragonWave®, Horizon® and Avenue® are registered trademarks of DragonWave Inc.

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to DragonWave’s growth opportunities and the potential benefits of, and demand for, DragonWave’s products. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of DragonWave’s products compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. DragonWave’s actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of DragonWave to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by DragonWave with U.S. and Canadian securities regulatory authorities. DragonWave assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Media Contact:
Nadine Kittle
Marketing Communications
DragonWave Inc.
nkittle@dragonwaveinc.com
+1-613-599-9991 ext 2262

Media Contact:
Becky Obbema
Interprose
(for DragonWave)
Becky.Obbema@interprosepr.com
+1-408-778-2024

Investor Contact:
Peter Allen
CEO
DragonWave Inc.
pallen@dragonwaveinc.com
+1-613-599-9991

Thursday, April 14th, 2016 Uncategorized Comments Off on (DRWI) Successfully Completes First Five Harmony Enhanced MC Trials
Top Small Cap Market News